PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31529315-9 2020 Moreover, it sensitized cells to the chemotherapeutic agents such as cisplatin, pemetrexed, and etoposide (VP-16), and this effect by dinaciclib may induce cell cycle arrest via abrogating CDK2 activity. Etoposide 96-105 host cell factor C1 Homo sapiens 107-112 33389482-2 2021 BACKGROUND: A combination of etoposide (VP-16) and cisplatin (CDDP) is the standard treatment for certain colon cancers. Etoposide 29-38 host cell factor C1 Homo sapiens 40-45 32547627-2 2020 Etoposide (VP-16), an inhibitor of nuclear enzyme deoxyribonucleic acid (DNA)-topoisomerase II, has shown activity in brain tumors. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 32048620-16 2019 A combination of oral etoposide (VP-16) and pazopanib needs further evaluation in a large number of patients in a randomized trial. Etoposide 22-31 host cell factor C1 Homo sapiens 33-38 31583565-1 2020 Etoposide (VP-16) is the topoisomerase 2 (Top2) inhibitor used for treating of glioma patients however at high dose with serious side effects. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 30606675-2 2019 So, we design and prepare acid-controlled release complexes of podophyllotoxin (POD) and etoposide (VP-16) with pH-labile acyclic cucurbit[n]urils, and their characteristics and inclusion complexation behaviors were investigated via fluorescence spectroscopy, nuclear magnetic resonance and X-ray power diffraction. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 31615546-11 2019 The evolution was favorable under a treatment including etoposide (VP-16). Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 31438997-3 2019 METHODS: We used the transwell chamber assay to test effects of Topoisomerase inhibitors Etoposide (VP-16), Adriamycin (ADM) and Irinotecan (CPT-11) on the migration and invasion of cancer cells. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 28906490-9 2017 Cells with lower levels of POPX2 exhibit higher TAK1 activity in response to etoposide (VP-16) treatment. Etoposide 77-86 host cell factor C1 Homo sapiens 88-93 30297860-2 2018 The mechanism of the Top2s poisons such as etoposide (VP-16) was reported as stabilizing the Top2-DNA complex and engendering permanent DNA breakage. Etoposide 43-52 host cell factor C1 Homo sapiens 54-59 29886322-3 2018 As a result, most of the compounds were more potent than the positive drugs Etoposide (VP-16) and Doxorubicin which were widely used in clinical for antitumor. Etoposide 76-85 host cell factor C1 Homo sapiens 87-92 28959361-1 2017 The present study aimed to investigate the effect of various concentrations of etoposide (VP-16) on the E3 ubiquitin-protein ligase Mdm2 (Mdm2)-retinoblastoma (Rb) signaling pathway in the cellular senescence of A549 lung adenocarcinoma cells. Etoposide 79-88 host cell factor C1 Homo sapiens 90-95 28587258-3 2017 Here we report a combination of ICG-PDT with a chemotherapy drug etoposide (VP-16), aiming to enhance the anticancer efficacy, to circumvent limitations of PDT using ICG, and to reduce side effects of VP-16. Etoposide 65-74 host cell factor C1 Homo sapiens 76-81 28587258-3 2017 Here we report a combination of ICG-PDT with a chemotherapy drug etoposide (VP-16), aiming to enhance the anticancer efficacy, to circumvent limitations of PDT using ICG, and to reduce side effects of VP-16. Etoposide 65-74 host cell factor C1 Homo sapiens 201-206 27903968-7 2017 In addition, bosutinib enhanced doxorubicin (Dox)- and etoposide (VP-16)-induced cytotoxicity in NB cells. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 29088754-1 2017 miR-302a have been reported to participate in various physiological and pathological processes, however, a role for miR-302a in etoposide (VP-16) resistance of acute myeloid leukemia (AML) has not been reported. Etoposide 128-137 host cell factor C1 Homo sapiens 139-144 28030535-1 2017 BACKGROUND: Etoposide (VP-16), a podophyllotoxin derivative, is used in conditioning regimens before allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia. Etoposide 12-21 host cell factor C1 Homo sapiens 23-28 27907860-1 2017 Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbon nanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphorothioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small and small cell lung cancer in vitro. Etoposide 160-169 host cell factor C1 Homo sapiens 171-176 27980999-4 2016 The fine properties synthetic SiO2@LDH-VP16 (VP16: etoposide) are practiced to exhibit the nanoparticle"s suppression on migration and invasion of non-small cell lung cancer (NSCLC). Etoposide 51-60 host cell factor C1 Homo sapiens 39-43 27840903-1 2016 This study investigated arsenic trioxide (As2O3), cisplatin (DDP) and etoposide (Vp16) on the anticancer effects and P-glycoprotein (P-gp) expression in neuroblastoma (NB) SK-N-SH cells. Etoposide 70-79 host cell factor C1 Homo sapiens 81-85 27639682-3 2016 Cellular uptake efficiencies of DC and DP in human alveolar type II epithelial cells were significantly enhanced compared to DMEP and etoposide (VP-16), which were demonstrated to be concentration-, time- and energy-dependent. Etoposide 134-143 host cell factor C1 Homo sapiens 145-150 27980999-4 2016 The fine properties synthetic SiO2@LDH-VP16 (VP16: etoposide) are practiced to exhibit the nanoparticle"s suppression on migration and invasion of non-small cell lung cancer (NSCLC). Etoposide 51-60 host cell factor C1 Homo sapiens 45-49 27174643-8 2016 In line with this, these cells are also more sensitive to the ROS-producing chemotherapeutic drugs etoposide/Vp16 and Ara-C. Etoposide 99-108 host cell factor C1 Homo sapiens 109-113 27378523-5 2016 Dinaciclib also significantly sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and etoposide (VP-16). Etoposide 129-138 host cell factor C1 Homo sapiens 140-145 27680712-2 2016 The therapeutic effects of etoposide(VP-16), a widely used anticancer agent, on HSCs apoptosis and liver fibrosis resolution are still unclear. Etoposide 27-36 host cell factor C1 Homo sapiens 37-42 27103979-3 2016 We investigated the efficacy and safety of chemo mobilization with an intermediate dose etoposide (VP-16; 200 mg/m(2) on days 1-3) and granulocyte-colony stimulating factor (G-CSF)(5 microg/kg twice daily from day 4 through the final day of collection). Etoposide 88-97 host cell factor C1 Homo sapiens 99-104 28132989-6 2016 We administered two courses of systemic chemotherapy consisting of cisplatin (CDDP) plus an etoposide (VP-16), a first-line treatment usually administered to patients with small cell carcinoma of the lung. Etoposide 92-101 host cell factor C1 Homo sapiens 103-108 25772707-2 2015 Oral etoposide (VP-16) has previously been found to be clinically active in MBC patients in phase II trials. Etoposide 5-14 host cell factor C1 Homo sapiens 16-21 26046675-1 2015 Etoposide (VP-16), a topoisomerase II inhibitor, is an effective anti-cancer drug used for the treatment of non-small-cell lung cancer (NSCLC). Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 26146158-3 2015 In this paper we build an optimal control model to optimize the scheduling problem along one cycle of chemotherapy treatment using a single anticancer drug etoposide (VP-16). Etoposide 156-165 host cell factor C1 Homo sapiens 167-172 26040247-1 2015 The impact of etoposide (VP-16) plasma concentrations on the day of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on leukemia-free survival in children with acute lymphoblastic leukemia (ALL) was studied. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 26202083-4 2015 In the present study, we aimed to further clarify the interactions between PKCzeta, Bcl10 and other proteins co-immunoprecipitated from NMs isolated from untreated and etoposide (also known as VP-16; 2.0 microg/ml)-treated C4-I cells using biochemical and proteomics analyses. Etoposide 168-177 host cell factor C1 Homo sapiens 193-198 23700229-4 2013 Using a panel of neuroblastoma cell lines, we found that TAK1 inhibitor 5Z-7-oxozeaenol significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) on neuroblastoma cell lines. Etoposide 159-168 host cell factor C1 Homo sapiens 170-175 25737788-7 2015 Conventional induction therapy for HLH is dexamethasone and etoposide (VP-16), followed by or with cyclosporine. Etoposide 60-69 host cell factor C1 Homo sapiens 71-76 24649349-5 2014 Our results demonstrated that the topoisomerase-II inhibitor etoposide (VP-16) exhibited cytotoxic effects synergistically with 15d-PGJ2. Etoposide 61-70 host cell factor C1 Homo sapiens 72-77 31171989-3 2015 It has been found that both doxorubicin and etoposide (VP-16) act on topoisomerase II, induce DNA cleavage, and form double-strand breaks, causing tumor cell death. Etoposide 44-53 host cell factor C1 Homo sapiens 55-60 25011391-3 2014 Here, we monitored the interactions between protein kinase-Czeta (PKCzeta) and Bcl10 protein in untreated and etoposide (VP-16)-treated C4-I cells by means of a new combined morphological approach and validated it by taking stock of our previous proteomic and biochemical work (Chiarini et al. Etoposide 110-119 host cell factor C1 Homo sapiens 121-126 24262885-5 2013 Compound 3a showed comparable topoisomerase II inhibitory activity to etoposide (VP-16) at 100 muM concentration. Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 24049059-3 2013 Our previous studies indicated that ( NO/ NO-derived species react with etoposide (VP-16) in vitro and form products that show significantly reduced activity toward HL60 cells and lipopolysaccharide (LPS)-induced macrophages. Etoposide 72-81 host cell factor C1 Homo sapiens 83-88 24136231-6 2013 P22077 also significantly augmented the cytotoxic effects of doxorubicin (Dox) and etoposide (VP-16) in NB cells with an intact USP7-HDM2-p53 axis. Etoposide 83-92 host cell factor C1 Homo sapiens 94-99 22167279-9 2011 After primary surgical resection, 6 patients received chemotherapy with cisplatin (CDDP) and etoposide (VP-16). Etoposide 93-102 host cell factor C1 Homo sapiens 104-109 23605997-3 2013 We found that both TNFalpha, which induces the extrinsic apoptotic pathway, and etoposide (VP-16), which induces the intrinsic apoptotic pathway, stimulated U937V cell death without cell disintegration. Etoposide 80-89 host cell factor C1 Homo sapiens 91-96 23422328-6 2013 At Indiana University, we recommend etoposide (VP-16), ifosfamide and cisplatin (VIPx4) instead of bleomycin, etoposide and platinum (BEPx4) to prevent pulmonary complications, as these patients require extensive thoracic surgical resection. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 23065812-1 2013 Etoposide (VP-16) is a hydrophobic anticancer agent inhibiting Topoisomerase II, commonly used in pediatric brain chemotherapeutic schemes as mildly toxic. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 23613938-9 2013 Furthermore, using this reporter gene system, we found that etoposide (VP-16) and 5-fluorouracil (5-FU) activated miRNA-16 expression in vitro and in vivo, and the upregulation of miRNA-16 is p38MAPK dependent but NF-kappaB independent. Etoposide 60-69 host cell factor C1 Homo sapiens 71-76 22376221-1 2012 INTRODUCTION: Etoposide (VP16) is a drug used not only for the treatment of lymphoma but also for the collection of peripheral blood stem cells (PBSCs). Etoposide 14-23 host cell factor C1 Homo sapiens 25-29 23134856-1 2012 OBJECTIVE: To explore the effectivity and safety of single high-dose (HD) etoposide (Vp16) with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood stem cells (PBSC) in patients with hematologic malignancies. Etoposide 74-83 host cell factor C1 Homo sapiens 85-89 22791162-0 2012 Schedule-dependent cytotoxicity of etoposide (VP-16) and cyclophosphamide in leukemia cell line K-562. Etoposide 35-44 host cell factor C1 Homo sapiens 46-51 23353839-1 2012 OBJECTIVES: Etoposide (Vepesid, VP-16), an inhibitor of topoisomerase II, is a chemotherapeutic drug commonly used for treatment of different types of malignant diseases. Etoposide 12-21 host cell factor C1 Homo sapiens 32-37 23949216-2 2013 This results from a high resistance of GBM tumor cells to current therapeutic options, including etoposide (VP-16). Etoposide 97-106 host cell factor C1 Homo sapiens 108-113 23666235-2 2013 The aim of this multicenter phase I study is to establish the recommended dose (RD) of the combination therapy with temozolomide (TMZ) and oral etoposide (VP-16) in children with relapsed or refractory malignant glioma and brainstem glioma at diagnosis. Etoposide 144-153 host cell factor C1 Homo sapiens 155-160 22998676-4 2013 RESULTS: Similar to the TOP2-targeting drug, etoposide (VP-16), the NO-donor, S-nitrosoglutathione (GSNO), induces skin melanomas formation in 7,12-dimethyl- benz[a]anthracene (DMBA)-initiated mice. Etoposide 45-54 host cell factor C1 Homo sapiens 56-61 23402364-0 2013 Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213). Etoposide 65-74 host cell factor C1 Homo sapiens 76-81 23402364-2 2013 Here, we examined the hypothesis that ( )NO generation contributes to cancer cell drug resistance toward the widely used anticancer drug Etoposide (VP-16). Etoposide 137-146 host cell factor C1 Homo sapiens 148-153 23242346-8 2013 Co-incubation with honokiol and etoposide (VP-16) activated a complex death modality, which was composed of necrotic cell death and apoptosis. Etoposide 32-41 host cell factor C1 Homo sapiens 43-48 22728163-5 2012 The treatment of normal human T lymphocytes and fibroblasts with chemotherapeutic agents doxorubicin (DOX) or etoposide (VP16) led to significant shortening of telomeres, down-regulation of telomerase activity, and diminished expression of telomerase reverse transcriptase (hTERT) and the telomere binding proteins TPP1 and POT1. Etoposide 110-119 host cell factor C1 Homo sapiens 121-125 22053010-1 2012 Etoposide (VP-16), a topoisomerase II inhibitor, is an effective anticancer drug currently used for the treatment of a wide range of cancers. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 22953108-3 2012 Concurrent chemoradiotherapy using cisplatin (CDDP) and etoposide (VP-16) was given, which achieved complete response (CR). Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 21159109-1 2011 Etoposide (VP-16) is one of the most widely used antitumor agents in pediatric oncology as well as chemotherapeutic agents used in conditioning regimen prior to allo-HSCT for childhood ALL. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 20352292-1 2011 Etoposide (VP-16), a topoisomerase II (Topo II) inhibitor, has been widely used to treat malignancies. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 22593728-5 2011 The patient was started on chemotherapy with cisplatin (CDDP) and etoposide (VP-16), which had been reported to be effective for small-cell lung cancer. Etoposide 66-75 host cell factor C1 Homo sapiens 77-82 21176346-3 2010 The purpose of this study was to investigate the synergistic killing effect of SG611-pdcd5 and low-dose etoposide (VP-16) on K562 cells. Etoposide 104-113 host cell factor C1 Homo sapiens 115-120 19879873-2 2010 In our study, we found that it was more potent than etoposide (VP-16). Etoposide 52-61 host cell factor C1 Homo sapiens 63-68 20538454-2 2010 This study was designed to investigate the potential therapeutic benefit of combination therapy with temozolomide (TMZ) and oral etoposide (VP-16) in children with progressive or relapsed MB. Etoposide 129-138 host cell factor C1 Homo sapiens 140-145 20437127-2 2010 We report the results of three cases of limited-stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy. Etoposide 122-131 host cell factor C1 Homo sapiens 133-138 21163134-2 2010 This study aimed to investigate the mechanism of human small cell lung cancer cell line resistance to etoposide (VP-16), H446/VP. Etoposide 102-111 host cell factor C1 Homo sapiens 113-118 20596674-1 2010 Etoposide (VP-16) is a topoisomerase-II (topo II) inhibitor chemotherapeutic agent. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 20009466-6 2009 Although postoperative adjuvant chemotherapy consisting of carboplatin (CBDCA) +etoposide (VP-16) was administered, the patient died three months after surgery. Etoposide 80-89 host cell factor C1 Homo sapiens 91-96 20187579-0 2010 Hypoxia promotes etoposide (VP-16) resistance in neuroblastoma CHP126 cells. Etoposide 17-26 host cell factor C1 Homo sapiens 28-33 20187579-2 2010 Etoposide (VP-16), a drug commonly used in chemotherapy, leads to enhanced accumulation of cell populations in G2/M phase and increases levels of apoptosis as a topoisomerase II inhibitor. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 20094661-2 2010 The new compounds show improved potency and efficacy with respect to the parent molecule etoposide (VP-16), one of the semisynthetic derivatives of podophyllotoxin. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 18442869-13 2008 CL(VP16) and AUC(VP16) correlate significantly with overall survival of patients with SCLC patients receiving etoposide regimens. Etoposide 110-119 host cell factor C1 Homo sapiens 3-7 19920393-3 2009 We started combination chemotherapy with 5-fluorouracil (5-FU), Leucovorin (LV), etoposide (VP-16) and cis-diaminedichloroplatinum (CDDP) (designated as FLEP)in August 1999. Etoposide 81-90 host cell factor C1 Homo sapiens 92-97 19212831-1 2009 The upregulation of GRP78 and GRP94 under the induction of A23187 and its function in drug resistance to etoposide (VP-16) was investigated in human lung cancer cell line SK-MES-1. Etoposide 105-114 host cell factor C1 Homo sapiens 116-121 18504641-4 2009 We then treated the metastatic lesions with CBDCA and etoposide (VP-16), and were able to stop disease progression. Etoposide 54-63 host cell factor C1 Homo sapiens 65-70 18442869-1 2008 PURPOSE: To investigate the prognostic value of systemic exposure to etoposide (Area Under the concentration Curve (AUC(VP16))) on overall survival (OS) in patients with small cell lung cancer (SCLC). Etoposide 69-78 host cell factor C1 Homo sapiens 120-124 19734705-0 2009 [A case of primary small cell carcinoma of the esophagus responding remarkably to carboplatin (CBDCA) + etoposide (VP-16) combination therapy and radiation therapy]. Etoposide 104-113 host cell factor C1 Homo sapiens 115-120 19734705-2 2009 Carboplatin (CBDCA) + etoposide (VP-16) combination chemotherapy and radiation therapy was performed. Etoposide 22-31 host cell factor C1 Homo sapiens 33-38 19996654-1 2009 OBJECTIVES: To investigate the safety and efficacy in terms of PSA response of a low-dose oral combination of estramustine phosphate (EMP) and etoposide (VP16) in hormone- refractory prostate cancer (HRPC) patients. Etoposide 143-152 host cell factor C1 Homo sapiens 154-158 18442869-13 2008 CL(VP16) and AUC(VP16) correlate significantly with overall survival of patients with SCLC patients receiving etoposide regimens. Etoposide 110-119 host cell factor C1 Homo sapiens 17-21 18183572-4 2008 But we further show that treatment of cells with VP-16 (etoposide), an inhibitor of DNA topoisomerase II widely used in anticancer chemotherapy, causes the ETO gene repositioning which allows AML1 and ETO genes to be localized in the same nuclear layer. Etoposide 56-65 host cell factor C1 Homo sapiens 49-54 18503785-7 2008 Cross-resistance to adriamycin, vincristine and etoposide (VP-16) was consistent with overexpression of P-glycoprotein (P-gp). Etoposide 48-57 host cell factor C1 Homo sapiens 59-64 18071290-0 2008 Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin"s lymphoma. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 18292947-3 2008 PSP treatment enhanced the cytotoxicity of doxorubicin (Doxo), etoposide (VP-16) but not cytarabine (Ara-C). Etoposide 63-72 host cell factor C1 Homo sapiens 74-79 17918772-2 2008 We previously reported the effectiveness of low dose cytarabine (Ara-C) and etoposide (VP-16) (AV therapy) for those elderly AML patients ineligible for intensive chemotherapy. Etoposide 76-85 host cell factor C1 Homo sapiens 87-92 18036819-3 2008 VETOPEC, a combination of vincristine (VCR), etoposide (VP-16) and escalated dose cyclophosphamide (CPA), has been shown to be highly active in clinical trials. Etoposide 45-54 host cell factor C1 Homo sapiens 56-61 17260735-0 2006 [Studies on the electron transfer between etoposide (VP-16) and DNA]. Etoposide 42-51 host cell factor C1 Homo sapiens 53-58 17697545-4 2007 The inhibitory effects of cisplatin (DDP), vincristine (VCR), adriamycin (ADM) and etoposide (VP-16) used alone or in combination with tetrandrine on the proliferation of KB-3-1 and KB-MRP1 cells were evaluated by MTT assay. Etoposide 83-92 host cell factor C1 Homo sapiens 94-99 17578914-1 2007 Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clinical use. Etoposide 57-66 host cell factor C1 Homo sapiens 68-73 17168690-1 2006 Etoposide (VP-16), a DNA topoisomerase II poison widely used as an antineoplastic agent is also known to cause leukemia. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 17046572-4 2006 Following exposure to the topoisomerase II inhibitor, etoposide (VP-16), stromal cell MMP-2 protein expression is reduced. Etoposide 54-63 host cell factor C1 Homo sapiens 65-70 17490511-1 2007 MRE11 plays an important role in the signal transduction of DNA damage response, therefore this study was purposed to explore the relationship between hMRE11 focus formation and DNA double-strand breaks (DSBs) caused by etoposide (VP-16) in human promonocytic cells U937. Etoposide 220-229 host cell factor C1 Homo sapiens 231-236 17016621-8 2006 Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors. Etoposide 41-50 host cell factor C1 Homo sapiens 52-57 17047652-1 2006 Etoposide (VP-16) is a topoisomerase II (topo II) inhibitor chemotherapeutic agent. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 17260735-1 2006 In the present study, the electron transfer between Etoposide (VP-16) and GMP or DNA was investigated using pulse radiolysis and circular dichroism technology. Etoposide 52-61 host cell factor C1 Homo sapiens 63-68 16281866-2 2005 After 4 courses of chemotherapy with cisplatin (CDDP), etoposide (VP-16) and bleomycin hydrochloride (BLM), the mediastinal mass reduced in size significantly and the serum AFP level reached within normal range. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 16818517-5 2006 We envisioned that dp-VP16 would be converted to the active chemotherapeutic agent VP-16 by the same rabbit carboxylesterase (rCE) that we have previously shown to efficiently activate the prodrug irinotecan (CPT-11). Etoposide 83-88 host cell factor C1 Homo sapiens 22-26 16613690-2 2006 This study was to observe the efficacy and side effect of intrapericardial infusion of etoposide (VP-16) and cisplatin (DDP) on malignant pericardial effusion of non-small cell lung cancer (NSCLC). Etoposide 87-96 host cell factor C1 Homo sapiens 98-103 16875555-6 2006 FCM Annexin V-FITC/PI dual labeling technique was performed to investigate the etoposide (Vp16) induced NB4/VEGF-C cells apoptosis and bcl-2 gene expression level in these cells was analysed by RQ-PCR. Etoposide 79-88 host cell factor C1 Homo sapiens 90-94 16787360-2 2006 Their capability to restore/potentiate the antiproliferative activity of clinically useful drugs, such as doxorubicin (Doxo), vincristine (VCR) and etoposide (VP16), in drug-resistant human nasopharyngeal carcinoma KB cells (KB(WT), KB(MDR), KB(7D)and KB(V20C)) was evaluated. Etoposide 148-157 host cell factor C1 Homo sapiens 159-163 16110520-6 2005 Of pharmacological importance is the fact that most of these found-in-wine water-soluble ellagitannin derivatives are much more potent than etoposide (VP-16) at inhibiting top2-mediated DNA decatenation in vitro (top2=topoisomerase II)). Etoposide 140-149 host cell factor C1 Homo sapiens 151-156 16002426-1 2005 We conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etoposide (VP-16) 40 to 60 mg/kg (day -4) and cyclophosphamide 100 mg/kg (day -2) followed by autologous stem cell transplantation (ASCT) in 31 patients with CD20+ non-Hodgkin lymphoma (NHL). Etoposide 99-108 host cell factor C1 Homo sapiens 110-115 16465425-4 2006 MVP protein levels were enhanced in SW-620 cells after a 72 h treatment with doxorubicin (Adr), etoposide (VP-16), cis-platinum (II) diammine dichloride (CDDP) or SN-38, but not vincristine (VCR) or paclitaxel (Taxol) at their IC50 concentration. Etoposide 96-105 host cell factor C1 Homo sapiens 107-112 15927428-2 2005 Our treatment consisted of carboplatin (CBDCA) and etoposide (VP-16) in the same way as small cell carcinoma of the lung is treated. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 16086873-1 2005 BACKGROUND & OBJECTIVE: Etoposide (VP-16) is one of the most common chemotherapy drugs, but its usage is limited by drug resistance. Etoposide 28-37 host cell factor C1 Homo sapiens 39-44 16077943-7 2005 Furthermore, like AMR and AMROH, adriamycin (ADM) and etoposide (VP-16) are DNA topoisomerase II inhibitors, and the effects of these 4 agents on 44 degrees C hyperthermia were compared. Etoposide 54-63 host cell factor C1 Homo sapiens 65-70 15896459-0 2005 Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 15896459-1 2005 In this work, we described the proliferation of human non-small-cell-lung-cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo. Etoposide 195-204 host cell factor C1 Homo sapiens 206-211 15909125-0 2005 Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 16050481-11 2005 We performed pelvic radiotherapy, and chemotherapy using carboplatin (CBDCA) and etoposide (VP-16). Etoposide 81-90 host cell factor C1 Homo sapiens 92-97 15658872-1 2005 Etoposide (VP-16) is a potent human DNA topoisomerase II poison, derived from 4"-demethylepipodophyllotoxin, widely used in cancer chemotherapy. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 15735914-3 2005 The authors used combination of lower doses of both cisplatin and carboplatin combined with etoposide (VP-16) to minimize side effects of these agents. Etoposide 92-101 host cell factor C1 Homo sapiens 103-108 15751272-6 2005 Etoposide (VP-16) accumulation and efflux studies were carried out in the parental cell lines and their drug resistant cell lines. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 17343329-0 2005 Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: a phase II study. Etoposide 19-28 host cell factor C1 Homo sapiens 12-17 17343329-1 2005 PURPOSE: This phase II study was conducted to evaluate the efficacy and tolerability of vinorelbine (navelbine) and oral VP-16 (etoposide) in pretreated metastatic breast cancer (MBC) patients. Etoposide 128-137 host cell factor C1 Homo sapiens 121-126 15843892-1 2005 Procaspase-2S has been reported to selectively prevent membrane blebbing and apoptotic body formation in human monocytic-like leukemic U937 cells after etoposide (VP-16) treatment (Droin et al., Oncogene 20. Etoposide 152-161 host cell factor C1 Homo sapiens 163-168 15676214-1 2005 OBJECTIVE: Chemotherapy agents (CA) such as cytosine arabinoside (ara-C), idarubicin (IDA), and etoposide (VP-16) are widely used in the treatment of acute myeloid leukemia (AML) However, their effects on signaling pathways leading to cytotoxicity have only been described recently. Etoposide 96-105 host cell factor C1 Homo sapiens 107-112 15617835-5 2005 Functional blockade by TOS of MRP1 was confirmed by the enhanced accumulation of etoposide (VP-16), an MRP1-substrate drug. Etoposide 81-90 host cell factor C1 Homo sapiens 92-97 15634660-1 2004 During camptothecin- and etoposide (VP-16)-induced apoptosis in HL-60 cells, the expression level of cell death receptor-3 (DR3), cell death receptor-4 (DR4), and FAS remained mostly unchanged, whereas the expression of silencers of death domain (SODD) and FLICE inhibitory proteins, inhibitors of the cell death receptor signaling pathways, decreased substantially. Etoposide 25-34 host cell factor C1 Homo sapiens 36-41 14966827-1 2004 BACKGROUND: Etoposide (VP-16) is a topoisomerase II inhibitor that is effective in a broad spectrum of pediatric and adult malignancies. Etoposide 12-21 host cell factor C1 Homo sapiens 23-28 15631665-1 2004 The aim was to study the protective effects of amifostine (AMF) on normal hematopoietic stem/progenitor cells against the chemotherapeutic damage from etoposide (VP-16). Etoposide 151-160 host cell factor C1 Homo sapiens 162-167 15510828-3 2004 In April 2002, while in non-complete remission, she subsequently underwent total body irradiation (TBI) and treatment with cyclophosphamide (CY) and etoposide (VP-16) before receiving an allogeneic peripheral blood stem cell transplant from her HLA-identical brother. Etoposide 149-158 host cell factor C1 Homo sapiens 160-165 15254227-4 2004 In MDA-MB231 breast cancer cells treated with etoposide (VP16), active caspase 8 is detected only in the membrane fraction, which contains both mitochondria and endoplasmic reticulum (ER), as revealed by fractionation studies. Etoposide 46-55 host cell factor C1 Homo sapiens 57-61 15205610-4 2004 In contrast, the average IC50 values of adriamycin (ADM), 4"-epidoxorubicin (EDR), mitomycin C (MMC), cisplatin and vepesid (VP-16) were 0.96, 0.74, 2.81, 7.27 and 26.66 microM, respectively. Etoposide 116-123 host cell factor C1 Homo sapiens 125-130 15312348-1 2004 OBJECTIVE: To observe the combined effect of etoposide (Vp-16) and recombinant human granulocyte colony-stimulating factor (rhG-CSF) on mobilization of autologous peripheral blood stem cells (APBSC) in malignant tumor patients and find out the suitable dose of Vp-16. Etoposide 45-54 host cell factor C1 Homo sapiens 56-61 14750184-7 2004 The effects of cisplatin (CDDP) and etoposide (VP-16) on the HL-60 cultured in vivo were in good agreement with those obtained by a conventional colorimetric assay. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 12924948-2 2003 Like MRP1, MRP3 confers resistance to etoposide (VP-16) and actively transports 17 beta-estradiol 17-(beta-D-glucuronide) (E(2)17 beta G), cysteinyl leukotriene 4 (LTC(4)), and methotrexate, although with generally lower affinity. Etoposide 38-47 host cell factor C1 Homo sapiens 49-54 14513771-0 2003 [Investigation of the cause of polyurethane catheter cracking during constant infusion of etoposide (VP-16) injection (2)--Analysis of ethanol eluting materials from catheter]. Etoposide 90-99 host cell factor C1 Homo sapiens 101-106 14513771-1 2003 We studied the cause of cracking of clinically used polyurethane (PU) catheters during the constant infusion of etoposide (VP-16) injection (Lastet inj.) Etoposide 112-121 host cell factor C1 Homo sapiens 123-128 15035084-2 2004 After 3 courses of chemotherapy with cisplatin (CDDP) and etoposide (VP-16), the serum level decreased to normal range. Etoposide 58-67 host cell factor C1 Homo sapiens 69-74 14693066-2 2003 This study was designed to evaluate the response and tolerance of oxaliplatin,leucovorin (LV), 5-fluorouracil (5-FU),and etoposide (VP-16) as first-line regimen in advanced gastric cancer, and compare with traditional chemotherapy regimen. Etoposide 121-130 host cell factor C1 Homo sapiens 132-137 14714958-5 2003 Combination chemotherapy with cisplatin and etoposide (VP16) was administered to control tumor progression, and achieved marked therapeutic effects. Etoposide 44-53 host cell factor C1 Homo sapiens 55-59 12673724-4 2003 METHODS: The authors conducted a Phase I study of temozolomide in combination with escalating doses of oral etoposide (VP-16) to determine the maximum tolerated doses of these two agents when given together. Etoposide 108-117 host cell factor C1 Homo sapiens 119-124 12703990-3 2003 This study was designed to investigate the experimental therapeutic effect of the combination of topoisomerase I inhibitor hydroxycamptothecin (HCPT) with topoisomerase II inhibitor etoposide (VP-16) on nasopharyngeal carcinoma (NPC), the effect of the combination of HCPT with VP-16 against NPC was studied in vitro and in vivo. Etoposide 182-191 host cell factor C1 Homo sapiens 193-198 12703990-3 2003 This study was designed to investigate the experimental therapeutic effect of the combination of topoisomerase I inhibitor hydroxycamptothecin (HCPT) with topoisomerase II inhibitor etoposide (VP-16) on nasopharyngeal carcinoma (NPC), the effect of the combination of HCPT with VP-16 against NPC was studied in vitro and in vivo. Etoposide 182-191 host cell factor C1 Homo sapiens 278-283 12907245-4 2003 Vinblastine, doxorubicin, or etoposide (VP-16) induced apoptotic cell death in KB-3 carcinoma cells, with similar kinetic profiles of PARP cleavage, caspase 3 activation, and mitochondrial cytochrome c release. Etoposide 29-38 host cell factor C1 Homo sapiens 40-45 12885813-2 2003 To evaluate response to 2-chlorodeoxyadenosine (2-CDA) and etoposide (VP-16) in patients who did not respond to mitoxantrone and cytarabine. Etoposide 59-68 host cell factor C1 Homo sapiens 70-75 12656744-0 2003 Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Etoposide 23-32 host cell factor C1 Homo sapiens 34-39 12569581-9 2003 FR901228 also effectively inhibited growth of etoposide-resistant UMCC-1/VP-16, irinotecan-resistant PC-6/SN2-5H and cisplatin-resistant H526/CDDP cells having decreased expression of hTERT mRNA and telomerase activity, as well as their parental cells. Etoposide 46-55 host cell factor C1 Homo sapiens 66-78 12621489-0 2003 Etoposide (VP-16) plus G-CSF mobilizes different dendritic cell subsets than does G-CSF alone. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 12579475-0 2003 Results of phase I-II trial of concomitant hyperfractionated radiation and oral etoposide (VP-16) in patients with unresectable squamous cell carcinoma of the head and neck. Etoposide 80-89 host cell factor C1 Homo sapiens 91-96 12169392-1 2002 Etoposide (VP-16) is an anticancer agent that induces apoptosis in human leukemic cell lines such as U937 and HL60. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 12520751-1 2002 BACKGROUND & OBJECTIVE: EP regimen[etoposide (VP-16) + cisplatin (DDP)] is a standard regimen for treatment of small cell lung cancer (SCLC), but the cure rate is still low. Etoposide 39-48 host cell factor C1 Homo sapiens 50-55 14586153-3 2003 The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy. Etoposide 15-24 host cell factor C1 Homo sapiens 26-31 12370750-4 2002 The HCT-8DDP/anti-MRP Rz cells were more sensitive to doxorubicin (DOX) and etoposide (VP-16) by 2.5- and 4.1-fold, respectively, compared with HCT-8DDP cells. Etoposide 76-85 host cell factor C1 Homo sapiens 87-92 12079522-9 2002 All cell lines were resistant to mitomycin-C (MMC) and etoposide (VP-16). Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 12154052-1 2002 The cytotoxic effect of the chemotherapeutic drug etoposide (VP-16) is thought to result from its ability to induce DNA damage and thereby to trigger apoptosis. Etoposide 50-59 host cell factor C1 Homo sapiens 61-66 12391694-4 2002 They underwent 2 courses of systemic chemotherapy [cisplatin (CDDP) + etoposide (VP-16)] with concurrent radiotherapy (40 Gy). Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 12209353-0 2002 The efficacy of prophylactic outpatient antibiotics for the prevention of neutropenic fever associated with high-dose etoposide (VP-16) for stem cell mobilization. Etoposide 118-127 host cell factor C1 Homo sapiens 129-134 12076523-8 2002 The inhibition of the VP-16-induced MPT by antioxidants agrees with the prevention of etoposide-induced apoptosis by GSH and NAC and suggests the generation of oxidant species as a potential mechanism underlying the MPT that may trigger the release of mitochondrial apoptogenic factors responsible for apoptotic cascade activation. Etoposide 86-95 host cell factor C1 Homo sapiens 22-27 12076523-1 2002 Etoposide (VP-16) is known to promote cell apoptosis either in cancer or in normal cells as a side effect. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 12018110-1 2002 A 48-year-old woman with small-cell lung cancer received combined chemotherapy consisting of cisplatin (CDDP) and etoposide (Vp-16). Etoposide 114-123 host cell factor C1 Homo sapiens 125-130 12513833-1 2002 The objective of this study was to explore the effect of p21(WAF1) on the sensitivity to chemotherapeutic agent VP-16, etoposide, in leukemia cell line K562. Etoposide 119-128 host cell factor C1 Homo sapiens 112-117 11942326-4 2002 Here we demonstrate that cisplatin (CDDP) and etoposide (VP-16) induce nuclear translocation of NF-kappaB in prostate cancer cell lines, followed by secretion of IL-6. Etoposide 46-55 host cell factor C1 Homo sapiens 57-62 11968736-6 2002 The cancer was clinically diagnosed as stage C. Pelvic radiotherapy combined with chemotherapy using cisplatin (CDDP) and etoposide (VP-16) was started according to the treatment for limited small cell cancer of the lung. Etoposide 122-131 host cell factor C1 Homo sapiens 133-138 11534713-3 2001 It was possible to separate the substances 5-fluorouracil (5-FU), methotrexate (MTX), 7-hydroxymethotrexate (7-OH-MTX), and etoposide (VP-16) in one chromatographic run. Etoposide 124-133 host cell factor C1 Homo sapiens 135-140 11585429-0 2001 Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival. Etoposide 57-66 host cell factor C1 Homo sapiens 68-73 11585429-5 2001 Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. Etoposide 23-32 host cell factor C1 Homo sapiens 34-39 11473732-0 2001 Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation. Etoposide 48-57 host cell factor C1 Homo sapiens 59-64 11396179-7 2001 The MTT assay showed increased IC50 values or resistance to doxorubicin (DOX), etoposide (VP-16) and cisplatin (CDDP) in KB8-5/alpha MRP-Rz cells. Etoposide 79-88 host cell factor C1 Homo sapiens 90-95 11377013-0 2001 A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. Etoposide 91-100 host cell factor C1 Homo sapiens 102-107 11463801-1 2001 BACKGROUND: The aim of this study was to examine the effectiveness of radio-chemotherapy using nimustine hydrochloride (ACNU) and etoposide (VP-16) for malignant gliomas. Etoposide 130-139 host cell factor C1 Homo sapiens 141-146 11400655-5 2001 All the patients were treated with etoposide (VP-16), 200 mg/m2 for 3 consecutive days, with 15 cycles at intervals of 3 weeks between each cycle, followed by maintenance therapy with IFN-alpha. Etoposide 35-44 host cell factor C1 Homo sapiens 46-51 11468031-4 2001 In this work, we sought to enhance cytotoxic effect of etoposide (VP-16) by a PBR ligand, diazepam (DZ) in U-87 MG human glioma cells. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 11556390-2 2001 We studied the cytotoxic effects of exposure to topoisomerase I inhibitor SN-38 and topoisomerase II inhibitor etoposide (VP-16) in lung cancer cell line Ma-1 using WST-1 assay and isobologram analysis. Etoposide 111-120 host cell factor C1 Homo sapiens 122-127 11322928-4 2001 In this study, we show that down-regulation of VCAM-1 by the chemotherapeutic agent etoposide (VP-16) is associated with altered cellular localization of NF-kappaB. Etoposide 84-93 host cell factor C1 Homo sapiens 95-100 11471856-2 2001 This study examines the effect of the anti-cancer therapies CDDP, doxorubicin (ADM) and etoposide (VP-16) on the cell cycle and their cytotoxicity against two gastric carcinoma cell lines: MKN-28 (well differentiated) and MKN-45 (poorly differentiated). Etoposide 88-97 host cell factor C1 Homo sapiens 99-104 11115510-2 2001 Treatment of human nonsmall cell lung carcinoma (NSCLC-3 or NSCLC-5) cells with the topo I poison SN-38 or the topo II poison etoposide (VP-16) leads to activation of NF-kappaB before induction of apoptosis. Etoposide 126-135 host cell factor C1 Homo sapiens 137-142 11275460-1 2001 Chronic oral VP-16 (etoposide) is a chemotherapy regimen with a wide application in oncology and documented efficacy against germ cell tumors, lymphomas, Kaposi"s sarcoma, and primary brain tumors. Etoposide 20-29 host cell factor C1 Homo sapiens 13-18 10898537-0 2000 Plasma pharmacokinetics of etoposide (VP-16) after i.v. Etoposide 27-36 host cell factor C1 Homo sapiens 38-43 11269739-0 2001 Differential sensitivity to etoposide (VP-16)-induced S phase delay in a panel of small-cell lung carcinoma cell lines with G1/S phase checkpoint dysfunction. Etoposide 28-37 host cell factor C1 Homo sapiens 39-44 11269739-1 2001 PURPOSE: The highly schedule-dependent cytotoxic agent etoposide (VP-16) is initially effective in the treatment of small-cell lung cancer (SCLC), particularly in multidrug combination chemotherapy. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 11210163-3 2000 We conducted a phase II study of etoposide (VP-16)-ifosfamide-cisplatin (VIP) combination chemotherapy plus early concurrent thoracic irradiation for the patients with previously untreated limited small cell lung cancer in order to assess if the treatment modality could improve the response rate and the toxicity. Etoposide 33-42 host cell factor C1 Homo sapiens 44-49 10961896-3 2000 Modulation of cytarabine (Ara-C) and etoposide (VP-16) efficacy by bone marrow stromal cells in vitro was investigated. Etoposide 37-46 host cell factor C1 Homo sapiens 48-53 11038146-1 2000 PURPOSE: The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16. Etoposide 72-81 host cell factor C1 Homo sapiens 83-88 11038146-1 2000 PURPOSE: The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16. Etoposide 72-81 host cell factor C1 Homo sapiens 143-148 11225846-4 2000 When HL-60 cells were induced to undergo apoptosis by treating with 50 microM etoposide (VP-16) for 4 hours, 77 kDa and 40 kDa polypeptides accumulated in nuclear fractions. Etoposide 78-87 host cell factor C1 Homo sapiens 89-94 10825136-2 2000 The objective of the study was to elucidate whether other modes of DNA damage induced by doxorubicin, topotecan, and etoposide (VP-16) could elicit a similar cytotoxic response in TS- cells by signaling via the Fas death receptor. Etoposide 117-126 host cell factor C1 Homo sapiens 128-133 10901300-1 2000 We have previously reported that novobiocin potentiates the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26) in a number of experimental tumor cell lines by inhibition of the efflux of the epipodophyllotoxins by an ATP-requiring transporter. Etoposide 82-91 host cell factor C1 Homo sapiens 93-98 11232603-4 2000 We employed the anticancer drug, etoposide (VP-16), as a model phenolic compound to study the sensitivity of ryanodine-sensitive Ca2+ channel (RyR) to VP-16 phenoxyl radicals. Etoposide 33-42 host cell factor C1 Homo sapiens 44-49 11232603-4 2000 We employed the anticancer drug, etoposide (VP-16), as a model phenolic compound to study the sensitivity of ryanodine-sensitive Ca2+ channel (RyR) to VP-16 phenoxyl radicals. Etoposide 33-42 host cell factor C1 Homo sapiens 151-156 11137708-1 2001 The cell cycle phase-dependent induction of DNA damage and apoptosis by etoposide (VP-16) and its modulation by 1-[N,O-bis(1, 5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-piperazine (KN-62), an inhibitor of calcium-calmodulin-dependent enzymes, were examined in sensitive (HL-60/S) and VP-16-resistant (HL-60/DOX0.05) HL-60 cells. Etoposide 72-81 host cell factor C1 Homo sapiens 83-88 11137708-1 2001 The cell cycle phase-dependent induction of DNA damage and apoptosis by etoposide (VP-16) and its modulation by 1-[N,O-bis(1, 5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-piperazine (KN-62), an inhibitor of calcium-calmodulin-dependent enzymes, were examined in sensitive (HL-60/S) and VP-16-resistant (HL-60/DOX0.05) HL-60 cells. Etoposide 72-81 host cell factor C1 Homo sapiens 287-292 11112520-7 2000 Cell growth assays showed 5-fold and 14-fold increase in the IC(50) of HeLa-MRP1 to Rh123 and the Etoposide VP16 relative to HeLa cells, respectively. Etoposide 98-107 host cell factor C1 Homo sapiens 108-112 11213398-10 2000 Although randomized studies are not available, adjuvant therapy using other agents instead of mitotane (o,p-DDD), such as the combination of cisplatin and etoposide (VP-16), seems reasonable in the locally advanced stages. Etoposide 155-164 host cell factor C1 Homo sapiens 166-171 11008007-1 2000 PURPOSE: Cisplatin (CDDP) and etoposide (VP16) are considered major standard cytotoxic drugs for small cell lung cancer (SCLC). Etoposide 30-39 host cell factor C1 Homo sapiens 41-45 11042671-1 2000 Etoposide (VP-16) a topoisomerase II inhibitor induces apoptosis of tumor cells. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 10918425-3 2000 A total of 600 mg/m2 BCNU, 900 mg/m2 thiotepa and 1500 or 750 mg/m2 etoposide (VP-16) was administered followed by autologous bone marrow reinfusion (ABMR). Etoposide 68-77 host cell factor C1 Homo sapiens 79-84 11232603-0 2000 Reversible thiol-dependent activation of ryanodine-sensitive Ca2+ release channel by etoposide (VP-16) phenoxyl radical. Etoposide 85-94 host cell factor C1 Homo sapiens 96-101 10738279-3 2000 METHODS: Experimentally determined CFDs for VP-16 (etoposide)-induced apoptosis were measured by phosphotidylserine surface expression and mitochondrial membrane potential dissipation (DeltaPsi(m)) in BV173 leukemia cells. Etoposide 51-60 host cell factor C1 Homo sapiens 44-49 10786805-2 2000 It serves as a target for several useful antichemotherapeutic agents, such as etoposide (VP-16) and teniposide (VM26). Etoposide 78-87 host cell factor C1 Homo sapiens 89-94 10779024-1 2000 PURPOSE: The activity of etoposide (VP-16) has been demonstrated to be schedule-dependent. Etoposide 25-34 host cell factor C1 Homo sapiens 36-41 10898537-2 2000 The pharmacokinetics of etoposide (VP-16), a semi-synthetic derivative of podophyllotoxin, were studied in 16 pediatric patients (median age 8.3 years; range 4 months to 22 years) including two girls with Down"s syndrome (DS). Etoposide 24-33 host cell factor C1 Homo sapiens 35-40 11227493-1 2000 Apoptosis induced by etoposide (VP-16) in HL-60 cells was confirmed to be caspase-dependent. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 10713660-0 2000 Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). Etoposide 18-27 host cell factor C1 Homo sapiens 29-34 10540334-2 1999 Exposure of U937 cells to etoposide (VP-16) or the nitric oxide (NO) donor DETA-NO, both inducers of apoptosis in these cells, was associated with increased expression of the chemokines IL-8 and macrophage inflammatory protein-1 alpha. Etoposide 26-35 host cell factor C1 Homo sapiens 37-42 11154989-1 2000 It is known that the topoisomerase II inhibitors, MST-16 (sobuzoxane) and VP-16 (etoposide), are effective for the treatment of lymphoma. Etoposide 81-90 host cell factor C1 Homo sapiens 74-79 11216669-0 2000 Structure-activity studies of novobiocin analogs as modulators of the cytotoxicity of etoposide (VP-16). Etoposide 86-95 host cell factor C1 Homo sapiens 97-102 11216669-1 2000 We have previously reported that the antibiotic novobiocin enhanced the toxicity of the anticancer agent etoposide (VP-16) to several drug-sensitive and -resistant tumor cell lines. Etoposide 105-114 host cell factor C1 Homo sapiens 116-121 10587291-1 1999 The effect of tamoxifen (TAM) on the pharmacokinetics of oral administration of etoposide (VP-16) in patients with nonoperable hepatocellular carcinoma was investigated. Etoposide 80-89 host cell factor C1 Homo sapiens 91-96 10481938-2 1999 The combination of dose intensive etoposide (VP-16) followed by cyclophosphamide has clinical efficacy in the treatment of advanced breast cancer. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 10462537-1 1999 Etoposide (VP-16) is extensively used to treat cancer, yet its efficacy is calamitously associated with an increased risk of secondary acute myelogenous leukemia. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 10433362-1 1999 The purpose of these studies was to determine whether interferon-alpha (IFN-alpha) could enhance the sensitivity of human osteosarcoma cells to the cytotoxic actions of etoposide (VP-16). Etoposide 169-178 host cell factor C1 Homo sapiens 180-185 10471758-7 1999 The renal function partially recovered after a course of therapy combining VP-16 (etoposide) and dexamethasone and remained stable over 4-year follow-up. Etoposide 82-91 host cell factor C1 Homo sapiens 75-80 10472567-5 1999 Fourteen children with recurrent or advanced HB were additionally treated with carboplatin and etoposide (CARBO/VP 16), the reason being observations of drug resistance in children with HB after four or more courses of IPA-therapy in the HB 89 study. Etoposide 95-104 host cell factor C1 Homo sapiens 106-117 10414907-0 1999 Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 10328568-1 1999 The present paper investigates the pharmacokinetics of etoposide (VP-16) and carboplatin (CBDCA) in plasma and the cerebrospinal fluid (CSF), in the space left by tumor removal, of patients with glioma. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 10378670-1 1999 This phase I study was performed to assess the feasibility of combining cisplatin/etoposide (VP-16) with the arotinoid Ro 40-8757 and to determine the dose-limiting toxicity (DLT) of Ro 40-8757 in this combination. Etoposide 82-91 host cell factor C1 Homo sapiens 93-98 11240760-0 1999 Pregnancy outcome after treatment with etoposide (VP-16) for low-risk gestational trophoblastic tumor. Etoposide 39-48 host cell factor C1 Homo sapiens 50-55 10066381-2 1999 Incubation of U937 cells with 1-beta-d-arabinofuranosylcytosine or the etoposide VP-16 was accompanied by growth arrest in G0/G1 of the cell cycle and an accumulation of a population in the sub-G1 phase which exhibited characteristics typical for the apoptotic pathway. Etoposide 71-80 host cell factor C1 Homo sapiens 81-86 10368682-2 1999 In response to Etoposide (VP-16) induced DNA damage, cells undergo a G2-phase arrest resulting in the accumulation of inactive CDK1 (CDC2) kinase complexes. Etoposide 15-24 host cell factor C1 Homo sapiens 26-31 10205305-0 1999 Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16). Etoposide 108-117 host cell factor C1 Homo sapiens 119-124 10205305-1 1999 Etoposide (VP-16)-induced DNA strand breaks and repair and apoptosis of unstimulated human lymphocytes have been studied using DNA comet assay, electrophoresis of low-molecular-weight DNA extracts, and fluorescence microscopy. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 10064605-2 1999 In human cells treated with the topoisomerase inhibitors camptothecin or etoposide (VP-16), we find that RPA2, the middle-sized subunit of RPA, becomes rapidly phosphorylated. Etoposide 73-82 host cell factor C1 Homo sapiens 84-89 10066792-1 1999 A Ser740 --> Trp mutation in yeast topoisomerase II (top2) and of the equivalent Ser83 in gyrase results in resistance to quinolones and confers hypersensitivity to etoposide (VP-16). Etoposide 168-177 host cell factor C1 Homo sapiens 179-184 10084254-1 1999 We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Etoposide 101-110 host cell factor C1 Homo sapiens 112-117 10359142-2 1999 Camptothecin (CPT) and etoposide (VP-16) produced combination indices (CI) <1.0 in all glioma cell lines tested, including those that were relatively resistant to the two topoisomerase inhibitors individually. Etoposide 23-32 host cell factor C1 Homo sapiens 34-39 9921266-0 1998 [The cause of polyurethane catheter cracking during constant infusion of etoposide (VP-16) injection]. Etoposide 73-82 host cell factor C1 Homo sapiens 84-89 10555127-2 1999 The present study was designed to assess whether topotecan with cytosine arabinoside (ara-C) or with etoposide (VP-16) should be studied in phase II trials in patients with refractory or relapsed AML. Etoposide 101-110 host cell factor C1 Homo sapiens 112-117 14646472-8 1998 Apoptosis was induced by treatment with either the chemotherapeutic agent etoposide (VP-16 at 10 microM) over an 8 h period or with the anti-rheumatic agent hydroxychloroquine (HCQ at 0.28 mM) over a 24 h period. Etoposide 74-83 host cell factor C1 Homo sapiens 85-90 10089064-1 1998 It has been reported that aclarubicin inhibits etoposide (VP-16) induced cytotoxicity in human lung cancer cell lines (1, 2). Etoposide 47-56 host cell factor C1 Homo sapiens 58-63 9921266-1 1998 We studied the cause of cracking of a clinically used polyurethane (PU) catheter during the constant infusion of etoposide (VP-16) injection (Lastet), administered without dilution to patients as a part of combination high-dose chemotherapy. Etoposide 113-122 host cell factor C1 Homo sapiens 124-129 9744572-2 1998 Inhibitors of calcium-calmodulin-dependent enzymes sensitize resistant tumor cells to the topo II poison etoposide (VP-16) by enhancing DNA damage and an apoptotic response. Etoposide 105-114 host cell factor C1 Homo sapiens 116-121 10200532-6 1998 We demostrated by Western blotting assay that DXR and etoposide (VP-16) were able to induce CD95L expression after 4 h of treatment. Etoposide 54-63 host cell factor C1 Homo sapiens 65-70 9744573-6 1998 These were: bisdioxopiperazine (ICRF-187), a catalytic inhibitor of topoisomerase II, and etoposide (VP-16), an inducer of a cleavable complex of the enzyme with DNA. Etoposide 90-99 host cell factor C1 Homo sapiens 101-106 9691246-6 1998 The agents did not cause DNA protein linked breaks themselves; nevertheless, VP-16 [etoposide] induced DNA protein linked breaks were increased two fold in the presence of the agents suggesting synergistic effects. Etoposide 84-93 host cell factor C1 Homo sapiens 77-82 9730236-0 1998 Binding affinity of Cu(II)-VP-16 (etoposide) complex and its analogues to DNA and hydroxyl radical generation during DNA strand breaks. Etoposide 34-44 host cell factor C1 Homo sapiens 27-32 9730236-1 1998 Conformational effects and affinities of VP-16 (etoposide) and its derivatives to DNA in the presence of Cu(II) ion were examined by circular dichroic (CD) spectra. Etoposide 48-57 host cell factor C1 Homo sapiens 41-46 9508359-0 1998 Sister chromatid exchanges and DNA topoisomerase II inhibitors: effect of low concentrations of etoposide (VP-16) in ataxia telangiectasia lymphoblastoid cell lines. Etoposide 96-105 host cell factor C1 Homo sapiens 107-112 9719474-1 1998 KB/7D cells represent a multidrug-resistant subclone of human nasopharyngeal carcinoma KB cells generated by continuous exposure to the topoisomerase II inhibitor VP-16 (etoposide). Etoposide 170-179 host cell factor C1 Homo sapiens 163-168 9557789-4 1998 So-called "starburst cells," which have been purported to be specific for high-dose etoposide (VP-16) therapy, were seen in two cases, but only one of these patients received etoposide. Etoposide 84-93 host cell factor C1 Homo sapiens 95-100 9495807-0 1998 The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex. Etoposide 52-61 host cell factor C1 Homo sapiens 63-68 9495807-1 1998 Epipodophyllotoxin derivatives, such as etoposide (VP-16), constitute an important class of anticancer agents, the major cytotoxic effects of which are associated with trapping of the topoisomerase II/DNA cleavable complex and formation of protein-DNA cross-links and nicked DNA. Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 9434158-5 1998 Detection of topoisomerase II cleavages was strongly dependent upon one specific topoisomerase II poison, etoposide (VP-16). Etoposide 106-115 host cell factor C1 Homo sapiens 117-122 9570993-2 1998 cisplatin (CDDP) and etoposide (VP-16) as consolidation therapy following pathologically negative second-look surgical reassessment for Stage IIC-IV epithelial ovarian cancer (EOC). Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 9508359-1 1998 The correlation between etoposide (VP-16) cytotoxicity and the induction of sister chromatid exchanges (SCEs) suggested that the promotion of DNA recombination events may be crucial for the activity of antitopoisomerase drugs. Etoposide 24-33 host cell factor C1 Homo sapiens 35-40 9345336-2 1997 They are commonly used in combination with etoposide (VP-16) in chemotherapeutic regimens. Etoposide 43-52 host cell factor C1 Homo sapiens 54-59 9395460-6 1997 Camptothecin (CPT) and etoposide (VP-16) also markedly enhanced PKCalpha activity during apoptosis in HL60 cells. Etoposide 23-32 host cell factor C1 Homo sapiens 34-39 9371507-2 1997 For etoposide (VP-16), increased expression of MDR-1 or MRP and alterations in topoisomerase IIalpha have been shown to confer tolerance. Etoposide 4-13 host cell factor C1 Homo sapiens 15-20 9351548-10 1997 Group C was comprised of 2 patients with bone and visceral disease who were treated with etoposide (VP-16) + HDMP; at last follow-up, 1 patient was in CCR at 42+ months and the other patient, who had isolated vulvar recurrence 16 months later, was in CR with treatment with local IFN. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 9470808-1 1997 Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in chemotherapy-naive patients with malignant pleural mesothelioma. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 9413163-4 1997 These agents had little effect on in vitro L1210 DNA topoisomerase II activity at 100 microM but were able to cause synergistic increases in protein-linked DNA breaks when combined with etoposide (VP16). Etoposide 186-195 host cell factor C1 Homo sapiens 197-201 9334814-9 1997 Moreover, a significant correlation between MRP expression and chemoresistance against daunomycin (DM), doxorubicin (DOX), etoposide (VP-16) and vinblastine (VBL), but not cisplatin (CDDP) and bleomycin (Bleo) (MTT-based survival assay), was detected. Etoposide 123-132 host cell factor C1 Homo sapiens 134-139 9390699-1 1997 Chronic oral VP-16 (Etoposide) is a chemotherapy regimen with wide application in oncology and documented efficacy against germ cell tumors, lymphomas, Kaposi sarcoma, and glial brain tumors. Etoposide 20-29 host cell factor C1 Homo sapiens 13-18 9413193-4 1997 Clear correlations between the MRP gene level and the sensitivity to etoposide (VP-16) and doxorubicin (Dox) were observed except for one cell line which highly expressed DNA topoisomerase II. Etoposide 69-78 host cell factor C1 Homo sapiens 80-85 9331985-0 1997 Breaks in double-strand DNA by Cu(II) complexes of etoposide (VP-16) and its derivatives, as evaluated by S1 nuclease treatment. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 21528231-4 1997 This was also observed with lung cancer, the sensitivity of which to MMC, CDDP, vindesine (VDS) and etoposide (VP-16) was similar to the clinical efficacy. Etoposide 100-109 host cell factor C1 Homo sapiens 111-116 9311276-8 1997 In January 1996, following the conditioning regimen of nimustine hydrochloride, etoposide (VP-16), Ara-C, thiotepa, he received PBSCT. Etoposide 80-89 host cell factor C1 Homo sapiens 91-96 9266822-0 1997 Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16). Etoposide 111-120 host cell factor C1 Homo sapiens 122-127 9266822-1 1997 Etoposide (VP-16) is a widely used anticancer drug whose toxicity involves poisoning of topoisomerase II. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 16465270-2 1997 Exposure of L929 fibroblasts to tumor necrosis factor (TNF) or etoposide (VP-16) induced apoptotic death with similar kinetics. Etoposide 63-72 host cell factor C1 Homo sapiens 74-79 9639738-5 1997 RESULT: Ovarian carcinoma cells with positive MDR1 gene expression showed cross drug-resistance to ADM, daunorubicin (DNR), vincristine (VCR) and etoposide (VP-16), the value of inhibiting concentration (IC50) is 4.1-15.5 times of that of the cells with negative MDR1 gene expression. Etoposide 146-155 host cell factor C1 Homo sapiens 157-162 9230211-2 1997 Abnormal activation of cyclin B-associated CDC 2 kinase has been implicated in apoptosis induced by cancer chemotherapeutic agents such as paclitaxel (Taxol) and etoposide (VP-16). Etoposide 162-171 host cell factor C1 Homo sapiens 173-178 9193356-1 1997 PURPOSE: To present two patients as illustrations of the risk of developing secondary acute myelogenous leukemia (sAML) when theoretically safe doses of etoposide (VP-16) are used. Etoposide 153-162 host cell factor C1 Homo sapiens 164-169 9153428-2 1997 It is also the target of several clinically important antineoplastic agents such as the epipodophyllotoxin, VP-16 (etoposide). Etoposide 115-124 host cell factor C1 Homo sapiens 108-113 9124184-1 1997 The aim of this study was to define the efficacy of a combination of cisplatin, 5-fluorouracil (5-FU), leucovorin, and etoposide (VP-16) in locally advanced or metastatic non-small-cell lung cancer (NSCLC). Etoposide 119-128 host cell factor C1 Homo sapiens 130-135 9124193-2 1997 Carboplatin (CBDCA), etoposide (VP-16), and cyclophosphamide (CTX) combination therapy has proved activity against a wide variety of tumors. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 9096658-0 1997 Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans" cell histiocytosis in Italian and Austrian-German populations. Etoposide 48-57 host cell factor C1 Homo sapiens 59-64 9096658-1 1997 To estimate the risk of secondary leukemias after treatment with etoposide (VP-16), we evaluated subjects treated for Langerhans" cell histiocytosis (LCH) according to cooperative protocols in Italy or in Austria, Germany, Holland and Switzerland (AGDS). Etoposide 65-74 host cell factor C1 Homo sapiens 76-81 9137422-1 1997 We studied the combination effect of cisplatin(CDDP) plus etoposide(VP-16) in an established gastric cancer cell line, KATO-III, and also highly purified fresh human tumor cells obtained from 55 gastric cancer patients, using MTT assay. Etoposide 58-67 host cell factor C1 Homo sapiens 68-73 9241501-5 1997 From 1982 to 1986, patients received the BEP chemotherapy protocol which included cis-platinum, bleomycin and etoposide (VP 16). Etoposide 110-119 host cell factor C1 Homo sapiens 121-126 9377855-1 1997 BACKGROUND: Carboplatin (CBDCA), cyclophosphamide (CTX) and etoposide (VP-16) combination chemotherapy is active in many tumors. Etoposide 60-69 host cell factor C1 Homo sapiens 71-76 9194475-2 1997 Cisplatin (CDDP), etoposide (VP-16), and mitomycin C (MMC) are well-known anticancer agents that are also active against many of these types of cancer. Etoposide 18-27 host cell factor C1 Homo sapiens 29-34 9052763-1 1997 The mechanism of increased sensitivity to etoposide (VP-16) in a human bladder cancer cell line (J82/MMC-2), which is >9-fold more resistant to mitomycin C (MMC) compared with parental cells (J82/WT), was investigated. Etoposide 42-51 host cell factor C1 Homo sapiens 53-58 9095327-3 1997 In the SCLC cell line, supra-additive effect was observed for SN-38 in combination with cisplatin, etoposide (VP-16) and paclitaxel (Taxol). Etoposide 99-108 host cell factor C1 Homo sapiens 110-115 9044846-4 1997 We have investigated the relationships between gadd153 gene expression and apoptosis induction in four human leukemic cell lines with different sensitivities to apoptosis induced by etoposide (VP-16), a topoisomerase II inhibitor. Etoposide 182-191 host cell factor C1 Homo sapiens 193-198 9020192-2 1997 In this study, we found that either etoposide (VP-16) or camptothecin (CPT) activated c-Jun N-terminal kinase 1/stress-activated protein kinase (JNK1/SAPK), transient c-jun expression, and ICE (interleukin-1beta converting enzyme)/CED-3-like proteases in U937 cells. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 9306430-3 1997 The results demonstrate that deletions in the C-motif of NBD1 or the A-motif of NBD2 have a pronounced effect in reducing resistance levels to adriamycin, vincristine, or etoposide (VP-16). Etoposide 171-180 host cell factor C1 Homo sapiens 182-187 9073312-0 1997 Enhancement of etoposide (VP-16) cytotoxicity by enzymatic and photodynamically induced oxidative stress. Etoposide 15-24 host cell factor C1 Homo sapiens 26-31 9306577-3 1997 Sensitivity to cisplatin (CDDP) and etoposide (VP-16) was examined and each stable transfectant was more sensitive to these agents than the parental MCF-7 cells. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 9400948-1 1997 We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer. Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 9154130-1 1997 We investigated the effects of treatment of mitotic human fibroblasts with the topoisomerase II inhibitor etoposide (VP-16) on chromosome segregation at anaphase and the genetic consequence to daughter cells of topoisomerase inhibition during mitosis. Etoposide 106-115 host cell factor C1 Homo sapiens 117-122 9049828-5 1997 This could reduce the effectiveness of both cisplatin and etoposide (VP-16). Etoposide 58-67 host cell factor C1 Homo sapiens 69-74 8978799-0 1996 [Etoposide (VP-16) in gynecologic malignancy]. Etoposide 1-10 host cell factor C1 Homo sapiens 12-17 8978799-1 1996 Clinical application of etoposide (VP-16) for gynecologic malignancy has been investigated in trophoblastic disease, ovarian, endometrial and cervical cancer. Etoposide 24-33 host cell factor C1 Homo sapiens 35-40 8903480-5 1996 Sensitivity of the test samples to the anti-cancer drugs cisplatin (CDDP), doxorubicin (DXR) and etoposide (VP-16) was examined using the MTT?3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl [2H]-tetrazolium bromide? Etoposide 97-106 host cell factor C1 Homo sapiens 108-113 8940082-4 1996 Treatment with vinblastine or etoposide (VP-16) also activated JNK, with maximum increases of 6.5- and 4.3-fold, respectively. Etoposide 30-39 host cell factor C1 Homo sapiens 41-46 8932337-1 1996 Etoposide (VP-16) is an anti-cancer drug commonly used against several types of tumours and leukaemia, either alone or in combination chemotherapy. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8940736-8 1996 He then received chemotherapy consisting of ifosfamide (2 g/m2) and etoposide (VP-16) (100 mg/m2) given daily for 3 days every 3 weeks. Etoposide 68-77 host cell factor C1 Homo sapiens 79-84 8940736-11 1996 Ifosfamide and etoposide (VP-16), known for their usefulness in treatment of adult soft tissue sarcomas, can be used as salvage chemotherapy for patients with MFH who fail the front-line conventional chemotherapy. Etoposide 15-24 host cell factor C1 Homo sapiens 26-31 8898177-0 1996 A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Etoposide 35-44 host cell factor C1 Homo sapiens 46-51 8896444-1 1996 We investigated the role of proteases in the pathway that leads from specific DNA damage induced by etoposide (VP-16), a topoisomerase II inhibitor, to apoptotic DNA fragmentation in the U937 human leukemic cell line. Etoposide 100-109 host cell factor C1 Homo sapiens 111-116 8700130-2 1996 HL-60 cells selected in 0.05 micrograms/ml doxorubicin (DOX) are 10-fold and > 20-fold resistant to DOX and etoposide (VP-16), respectively. Etoposide 111-120 host cell factor C1 Homo sapiens 122-127 8814162-8 1996 When PCV had been given any time previously, only four (19%) of 21 patients responded to salvage chemotherapy; however, four (40%) of 10 patients who received etoposide (VP-16)/cisplatin (CDDP) responded. Etoposide 159-168 host cell factor C1 Homo sapiens 170-175 8882989-1 1996 A Phase I/II study of combination chemotherapy with cisplatin (CDDP), carboplatin (CBDCA) and etoposide (VP-16) (CPVP) was conducted in patients with small cell lung cancer. Etoposide 94-103 host cell factor C1 Homo sapiens 105-110 8759037-1 1996 Etoposide (VP-16)-resistant K562 cells (K/VP.5) were 26-fold resistant to VP-16, due in part to a reduction in DNA topoisomerase II (topoisomerase II) protein levels. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8759037-1 1996 Etoposide (VP-16)-resistant K562 cells (K/VP.5) were 26-fold resistant to VP-16, due in part to a reduction in DNA topoisomerase II (topoisomerase II) protein levels. Etoposide 0-9 host cell factor C1 Homo sapiens 74-79 8827879-3 1996 The plasma pharmacokinetics of adriamycin (ADR) and etoposide (VP-16) were investigated in these patients. Etoposide 52-61 host cell factor C1 Homo sapiens 63-68 8759037-0 1996 Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Etoposide 75-84 host cell factor C1 Homo sapiens 86-91 8673994-3 1996 Conversely, several studies on gastric carcinoma have demonstrated that the combination of etoposide (VP-16), leucovorin (LV), and 5-FU (ELF) is efficacious and moderately toxic. Etoposide 91-100 host cell factor C1 Homo sapiens 102-107 9000172-3 1996 We found that three topo II inhibitors, etoposide (VP-16), ICRF-193 and amsacrine (m-AMSA), greatly enhanced the frequency of G418r colonies. Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 8877478-1 1996 We investigated the modification of etoposide (i.e. VP-16)-induced cell killing by hyperthermia in a radioresistant human melanoma (Sk-Mel-3) and a human normal (AG1522) cell line. Etoposide 36-45 host cell factor C1 Homo sapiens 52-57 8665518-2 1996 TOP-53 exhibited twice the inhibitory activity of etoposide (VP-16) against topoisomerase II and induced DNA strand breaks but showed no inhibitory activity against tubulin polymerization. Etoposide 50-59 host cell factor C1 Homo sapiens 61-66 8602625-2 1996 To increase the efficacy of bone marrow transplantation (BMT), we have tried to add etoposide (VP-16) to busulfan/cyclophosphamide (BU/CY). Etoposide 84-93 host cell factor C1 Homo sapiens 95-100 8678544-0 1996 [Combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16) and 5"-DFUR, (MACVD therapy) as a second-line chemotherapy for metastatic gastric cancer: three cases]. Etoposide 44-53 host cell factor C1 Homo sapiens 55-60 9118302-6 1996 Actuarial five-year event-free survival (EFS) was similar in patients receiving fractionated total-body irradiation (FTBI) plus etoposide (VP-16) and cyclophosphamide (Cy) compared with chemotherapy alone consisting of carmustine (BCNU) plus identical doses of VP-16 and Cy (52% vs. 46%, p = 0.08). Etoposide 128-137 host cell factor C1 Homo sapiens 139-144 9387262-1 1996 From August 1984 to August 1994 ninety-one caese of malignant lymphoma (NHL 84 casese, HD 7 cases) were treated with Etoposide (VP-16) combinationn chemotherapy. Etoposide 117-126 host cell factor C1 Homo sapiens 128-133 8626112-2 1996 Preliminary reports suggested the combination of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) was sufficiently effective to warrant larger trials. Etoposide 86-95 host cell factor C1 Homo sapiens 97-102 8626125-0 1996 Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 8626125-1 1996 OBJECTIVE: The purpose of this study was to evaluate the efficacy of this three-drug regimen--hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16)--in patients with advanced or recurrent mixed mesodermal tumors (MMT) of the uterus who had not undergone previous chemotherapy. Etoposide 131-140 host cell factor C1 Homo sapiens 142-147 8609902-1 1996 Previous structure-activity studies of the antitumor compound etoposide (VP-16) have suggested that replacement of the glycoside moiety could afford therapeutically active analogues with different biochemical determinants for cellular accumulation and drug resistance. Etoposide 62-71 host cell factor C1 Homo sapiens 73-78 8635136-3 1996 Oral etoposide (VP-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tumors, and lymphomas, A synergistic effect between etoposide and alkylating agents such as estramustine was recently reported. Etoposide 5-14 host cell factor C1 Homo sapiens 16-21 8701487-0 1996 Treatment of X-linked lymphoproliferative disease (Duncan disease) with high-dose methylprednisolone and etoposide (VP-16). Etoposide 105-114 host cell factor C1 Homo sapiens 116-121 8635136-3 1996 Oral etoposide (VP-16) has shown clinical efficacy in advanced small cell lung carcinoma, breast cancer, germ cell tumors, and lymphomas, A synergistic effect between etoposide and alkylating agents such as estramustine was recently reported. Etoposide 167-176 host cell factor C1 Homo sapiens 16-21 8632756-2 1996 We found that etoposide (VP-16) induced apoptosis in human DU-145 prostatic carcinoma cells in a time- and concentration-dependent manner. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 8741246-1 1996 We report here a case of vasospastic angina following the administration of Carboplatin (CBDCA) and Etoposide (VP-16) in a patient with small cell lung carcinoma. Etoposide 100-109 host cell factor C1 Homo sapiens 111-116 20650183-1 1996 Phenoxyl radicals are inevitable intermediates in the oxidative enzymatic metabolism of a phenolic antitumour drug, etoposide (VP-16), by peroxidases, cytochrome P-450, prostaglandin synthetase and tyrosinase, as well as in its interactions with oxygen and peroxyl radicals. Etoposide 116-125 host cell factor C1 Homo sapiens 127-132 8699237-0 1996 Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. Etoposide 46-55 host cell factor C1 Homo sapiens 57-61 8551665-0 1996 An early phase II study of etoposide (VP-16) in advanced gastric cancer. Etoposide 27-36 host cell factor C1 Homo sapiens 38-43 20650183-0 1996 Reduction of phenoxyl radicals of the antitumour agent etoposide (VP-16) by glutathione and protein sulfhydryls in human leukaemia cells: Implications for cytotoxicity. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 9815936-1 1995 We characterized three human brain tumor cell lines (D54, HBT-20, and HBT-28) with respect to resistance to etoposide (VP-16), a topoisomerase II-reactive drug. Etoposide 108-117 host cell factor C1 Homo sapiens 119-124 9012539-1 1996 Recombinant human interleukin 1 alpha (rh IL-1 alpha) and etoposide (VP-16) synergize for direct growth inhibition of several human tumor cell lines in vitro. Etoposide 58-67 host cell factor C1 Homo sapiens 69-74 8546900-5 1996 The in vivo response of MDA435/LCC6 ascites to several cytotoxic drugs, including doxorubicin, etoposide (VP-16), BCNU and mitomycin C, closely reflects the activity of these single agents in previously untreated breast cancer patients. Etoposide 95-104 host cell factor C1 Homo sapiens 106-111 8895198-0 1996 Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Etoposide 65-74 host cell factor C1 Homo sapiens 76-81 8652276-1 1995 A phase II study was performed to evaluate the clinical and immunological effects of a regimen of cisplatin (DDP) and etoposide (VP-16) combined with thymosin-alpha 1 (TA1) and low-dose interferon-alpha 2a (IFN) in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Etoposide 118-127 host cell factor C1 Homo sapiens 129-134 8719068-0 1995 Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 7476909-0 1995 Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target. Etoposide 43-52 host cell factor C1 Homo sapiens 54-59 7476909-0 1995 Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target. Etoposide 43-52 host cell factor C1 Homo sapiens 208-213 7476909-0 1995 Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target. Etoposide 197-206 host cell factor C1 Homo sapiens 54-59 7476909-0 1995 Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C. We selected and characterized a 30-fold etoposide (VP-16)-resistant subline of K562 human leukemia cells (K/VP.5) that exhibits quantitative and qualitative changes in topoisomerase II, including hypophosphorylation of this drug target. Etoposide 197-206 host cell factor C1 Homo sapiens 208-213 8629231-9 1995 Postoperatively, the patient was treated initially with intravenous administration of ACNU and etoposide (VP16), resulting in a minor response of tumor regression. Etoposide 95-104 host cell factor C1 Homo sapiens 106-110 7545220-1 1995 PURPOSE: To evaluate the infertility rate in patients with germ cell tumors receiving chemotherapy with cisplatin, etoposide (VP-16), and bleomycin (PVP16B). Etoposide 115-124 host cell factor C1 Homo sapiens 126-131 8845473-1 1995 Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which is useful in the treatment of a wide variety of hematological malignancies and solid tumors. Etoposide 58-67 host cell factor C1 Homo sapiens 69-74 7636550-2 1995 Here we report the use of etoposide (VP-16) administered on a chronic oral schedule as a novel chemotherapeutic approach. Etoposide 26-35 host cell factor C1 Homo sapiens 37-42 7639514-0 1995 Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide (VP-16), inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical. Etoposide 94-103 host cell factor C1 Homo sapiens 105-110 7639514-3 1995 In the present work, we studied effects of phenoxyl radicals generated from a phenolic antitumor drug, Etoposide (VP-16), on oxidation of thiols and activity of Ca(2+)-ATPase in sarcoplasmic reticulum (SR) membranes from skeletal muscles. Etoposide 103-112 host cell factor C1 Homo sapiens 114-119 7640225-7 1995 Accordingly, the topoisomerase II-directed drug etoposide (VP-16) induced an increased number of DNA single-strand breaks in NYH/TPT cells. Etoposide 48-57 host cell factor C1 Homo sapiens 59-64 7622113-2 1995 The tumor was refractory to conventional multiagent chemotherapy that included intravenously administered etoposide (VP-16). Etoposide 106-115 host cell factor C1 Homo sapiens 117-122 7789893-0 1995 Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study. Etoposide 50-59 host cell factor C1 Homo sapiens 61-66 7611182-2 1995 Several of these agents, such as doxorubicin and etoposide (VP-16), are used to treat non-Hodgkin"s lymphomas (NHL). Etoposide 49-58 host cell factor C1 Homo sapiens 60-65 7789893-1 1995 Hexamethylmelamine (HMM) and oral etoposide (VP-16) have shown to be active against platinum-resistant epithelial ovarian cancer. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 7780971-9 1995 Cells were treated either with cisplatinum (CP), 4-hydroperoxy-cyclophosphamide (4-HC), or etoposide (VP-16) to induce apoptosis, and cell viability and DNA degradation were determined. Etoposide 91-100 host cell factor C1 Homo sapiens 102-107 7733847-2 1995 Etoposide (VP-16), administered on a long-term oral schedule, represents a novel chemotherapeutic approach. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 7645949-1 1995 Mechanisms of etoposide (VP-16) resistance have been evaluated in a human promyelocytic leukemia HL60 cell line. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 7707117-1 1995 PURPOSE: A phase II study of etoposide (VP-16) and carboplatin was performed in patients with extraocular retinoblastoma to evaluate the response rate with this drug combination. Etoposide 29-38 host cell factor C1 Homo sapiens 40-45 7738621-1 1995 PURPOSE: To evaluate the role of maintenance daily oral etoposide (VP-16) chemotherapy for germ cell patients who had a response to salvage therapy. Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 7738623-1 1995 PURPOSE: The study was undertaken to determine the activity and toxicity of oral etoposide (VP-16), ifosfamide, and cisplatin combination chemotherapy for previously treated, recurrent small-cell lung cancer (SCLC). Etoposide 81-90 host cell factor C1 Homo sapiens 92-97 7834606-0 1995 Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Etoposide 100-109 host cell factor C1 Homo sapiens 93-98 7716769-0 1995 Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 16892733-0 1995 Etoposide (VP-16) containing combination chemotherapy for treatment of patients with small cell lung cancer. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8527493-1 1995 We have studied the effect of the chemotherapeutic drug VP-16 (etoposide) on the metabolism of HeLa cells by analysing different cellular parameters considered as markers of apoptosis. Etoposide 63-72 host cell factor C1 Homo sapiens 56-61 7957669-3 1994 When U937 cells were treated with etoposide (VP-16), an inhibitor of DNA topoisomerase II, apoptosis occurred in a large number of cells, and flow-cytometric analysis revealed that the majority of cells in S phase underwent apoptosis within 2 h of the end of treatment. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 7754538-2 1995 METHODS: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. Etoposide 90-99 host cell factor C1 Homo sapiens 101-106 7947097-1 1994 As an approach to the rational design of combination chemotherapy involving the anti-cancer DNA topoisomerase II poison etoposide (VP-16), we have studied the dynamic changes occurring in small-cell lung cancer (SCLC) cell populations during protracted VP-16 exposure. Etoposide 120-129 host cell factor C1 Homo sapiens 131-136 7870198-1 1994 A slight induction of cellular differentiation (myelocytes and granulocytes) of HL-60 cells occurred after treatment with anti-tumor agents etoposide (VP-16), mitoxantrone (MXT), mitomycin C (MMC), actinomycin D (Act-D) or novobiocin (NOVO). Etoposide 140-149 host cell factor C1 Homo sapiens 151-156 7993115-1 1994 Phase I/II study of combination regimen composed of cisplatin (CDDP), carboplatin (CBDCA) and etoposide (VP-16) [CPVP] was conducted for small cell lung cancer. Etoposide 94-103 host cell factor C1 Homo sapiens 105-110 7993123-1 1994 Intraperitoneal administration of cisplatin (CDDP) etoposide (VP-16) and EAP therapy (combination chemotherapy with CDDP, adriamycin (ADM) and etoposide provided the curative resection for advanced gastric cancer with peritonitis carcinomatosa in a 48-year-old woman. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 8092107-2 1994 Etoposide (VP 16) is an antineoplastic agent that has major activity against a number of tumors, including germ cell neoplasms, small cell lung cancer, and malignant lymphoma. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 7969039-1 1994 Etoposide (VP-16) is one of several DNA-damaging agents that induce subcellular structural changes associated with apoptosis. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 7934159-1 1994 A child with acute myelomonocytic leukemia, bone marrow eosinophilia and inv(16) received first-line therapy including etoposide (VP-16). Etoposide 119-128 host cell factor C1 Homo sapiens 130-135 7523606-1 1994 PURPOSE: Estramustine and etoposide (VP-16) have been demonstrated to inhibit the growth of prostate cancer cells in experimental models. Etoposide 26-35 host cell factor C1 Homo sapiens 37-42 8075006-3 1994 The non-DNA intercalating topoisomerase II poison, etoposide (VP-16), is the "drug of first choice" in the treatment of LCH by cytotoxic chemotherapy. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 8055445-1 1994 BACKGROUND: The purpose of this study was to assess the ability of administering to patients induction chemotherapy with carboplatin and etoposide (VP-16), followed by full-course radiation therapy and weekly carboplatin with tolerable toxicity as preoperative therapy to down-stage disease thus allowing the resection of clinically staged IIIA non-small cell lung cancer. Etoposide 137-146 host cell factor C1 Homo sapiens 148-153 8037350-3 1994 etoposide (VP-16) at a dose of 150 mg/kg/day for 3 days. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8037350-8 1994 CONCLUSIONS: Etoposide (VP-16), an epipodophyllotoxin known for its usefulness in the treatment of malignancies of the monocyte/macrophage lineage, appears to be an effective treatment for the severe multisystem (disseminated) LCH of childhood and should be strongly considered as front-line therapy for this subgroup of patients with poor prognostic factors. Etoposide 13-22 host cell factor C1 Homo sapiens 24-29 7949251-1 1994 Etoposide (VP-16) and cisplatin are widely used in the treatment of malignancy. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8033146-1 1994 The chemotherapeutic drug etoposide (VP-16) causes the equilibrium reaction between noncleavable and cleavable topoisomerase II-DNA complexes to shift in favor of the cleavabel complex [H. Zang, P. D"Arpa, and L.F. Liu, Cancer Cells (Cold Spring Harbor), 2:23-27, 1990]. Etoposide 26-35 host cell factor C1 Homo sapiens 37-42 7948964-1 1994 A patient with secondary acute myelomonocytic leukemia after treatment with chronic oral etoposide (VP-16) for lung cancer is reported. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 8083718-1 1994 PURPOSE: The purpose of this phase I study was to determine the toxicities and response to continuous infusion carboplatin in combination with a fixed dose of etoposide (VP-16) in children with refractory acute leukemia. Etoposide 159-168 host cell factor C1 Homo sapiens 170-175 7934139-0 1994 Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). Etoposide 96-105 host cell factor C1 Homo sapiens 107-112 8021737-1 1994 PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity, and plasma concentrations of orally administered etoposide (VP-16) in pediatric oncology patients. Etoposide 129-138 host cell factor C1 Homo sapiens 140-145 8058057-1 1994 In this report we examine biochemical and genetic alterations in DNA topoisomerase II (topoisomerase II) in K562 cells selected for resistance in the presence of etoposide (VP-16). Etoposide 162-171 host cell factor C1 Homo sapiens 173-178 8027612-1 1994 We investigated the ability of camptothecin (CPT), an inhibitor of topoisomerase (topo) I, and etoposide (VP-16), an inhibitor of topo II, to potentiate X-radiation response and to inhibit the repair of potentially lethal damage (PLDR) and sublethal damage (SLDR) in confluent cultures of a radioresistant (Sk-Mel-3) and a radiosensitive (HT-144) human melanoma cell line. Etoposide 95-104 host cell factor C1 Homo sapiens 106-111 8021738-1 1994 PURPOSE: We used two different methods to administer high-dose etoposide (VP-16) during a myeloablative conditioning chemotherapy regimen before bone marrow transplantation (BMT). Etoposide 63-72 host cell factor C1 Homo sapiens 74-79 8201379-1 1994 PURPOSE: This study attempted to determine the efficacy of the combination of etoposide (VP-16), methyl-prednisolone, and cytarabine (Ara-C) with or without cisplatin in relapsing and refractory adult lymphoma patients. Etoposide 78-87 host cell factor C1 Homo sapiens 89-94 8078212-2 1994 An operation for lung cancer was performed in February 1991, and she was treated with etoposide (VP-16), a topoisomerase II inhibitor. Etoposide 86-95 host cell factor C1 Homo sapiens 97-102 7514153-6 1994 Both cell lines showed cross-resistance to a number of structurally unrelated cytotoxic drugs including anthracyclines and etoposide (VP-16), although only the CEM/A7 line was cross resistant to Vinca alkaloids. Etoposide 123-132 host cell factor C1 Homo sapiens 134-139 7908989-5 1994 The in vitro chemosensitivity of these cell lines to fluorouracil, doxorubicin, mitomycin C, cisplatin, and etoposide (VP-16) was determined using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetric assay. Etoposide 108-117 host cell factor C1 Homo sapiens 119-124 7728133-0 1994 Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Etoposide 8-17 host cell factor C1 Homo sapiens 19-24 8186529-3 1994 Postoperatively, she received 5-fluorouracil, cisplatin, and etoposide (VP-16) in conjunction with radiation therapy. Etoposide 61-70 host cell factor C1 Homo sapiens 72-77 7987995-1 1994 Vincristine (VCR) and etoposide (VP-16) have been shown to be synergistic in a murine model, and this combination was studied in a phase II trial. Etoposide 22-31 host cell factor C1 Homo sapiens 33-38 8142256-1 1994 K562 leukaemia cells were selected for resistance using 0.5 microM etoposide (VP-16). Etoposide 67-76 host cell factor C1 Homo sapiens 78-83 8128200-1 1994 Neutropenic typhlitis (NPT) was observed in 4 of 5 adult patients with acute leukemia treated with etoposide (VP16; 100 mg/m2/d for 6 days) and high-dose cytosine-arabinoside (HD ARAC, 2 g/m2 twice daily for 6 days) in a period of 11 months. Etoposide 99-108 host cell factor C1 Homo sapiens 110-114 7911742-1 1994 Etoposide (VP-16) is one of the most important anticancer agents available and is used in many chemotherapeutic regimens. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8033300-1 1994 To test the feasibility of a regimen of high-dose cisplatin, ifosfamide, and etoposide (VP-16; VIPP regimen), we registered 15 patients with advanced non-small-cell lung cancer in a phase I trial of the Northern California Oncology Group. Etoposide 77-86 host cell factor C1 Homo sapiens 88-93 8306412-3 1994 In etoposide (VP-16)-treated N231 but not PC-9 cells, DNA fragmentation continued to increase up to 42 h, and the increase was dependent on the concentration of VP-16. Etoposide 3-12 host cell factor C1 Homo sapiens 14-19 8306412-3 1994 In etoposide (VP-16)-treated N231 but not PC-9 cells, DNA fragmentation continued to increase up to 42 h, and the increase was dependent on the concentration of VP-16. Etoposide 3-12 host cell factor C1 Homo sapiens 161-166 7903202-1 1994 A human breast cancer cell line (MCF7/WT) was selected for resistance to etoposide (VP-16) by stepwise exposure to 2-fold increasing concentrations of this agent. Etoposide 73-82 host cell factor C1 Homo sapiens 84-89 7775129-1 1994 In previous studies, we found that VP-16 (etoposide) induced cytotoxicity and protein-concealed strand break formation was prevented in a small cell lung cancer (SCLC) cell line, when the cells were incubated with aclarubicin prior to treatment with VP-16. Etoposide 42-51 host cell factor C1 Homo sapiens 35-40 7775129-1 1994 In previous studies, we found that VP-16 (etoposide) induced cytotoxicity and protein-concealed strand break formation was prevented in a small cell lung cancer (SCLC) cell line, when the cells were incubated with aclarubicin prior to treatment with VP-16. Etoposide 42-51 host cell factor C1 Homo sapiens 250-255 7521931-6 1994 In case of incomplete tumor response, patients received a salvage chemotherapy consisting of three treatments with VP 16 (etoposide), ifosfamide, and cisplatinum. Etoposide 122-131 host cell factor C1 Homo sapiens 115-120 7910418-1 1994 Etoposide (VP-16) is used as an antineoplastic drug in humans. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 8501820-3 1993 It was postulated that estramustine phosphate (EMP), an estradiol-nitrogen mustard conjugate that binds to the nuclear matrix, might enhance the cytotoxicity of etoposide (VP-16), a topoisomerase II inhibitor that acts at the level of the nuclear matrix. Etoposide 161-170 host cell factor C1 Homo sapiens 172-177 8269627-1 1993 We have studied the effect of the chemotherapeutic drug VP-16 (etoposide) on the metabolism of HeLa cells by analysing different cellular parameters; in particular we have focused on changes in cellular morphology that are considered as markers of apoptosis. Etoposide 63-72 host cell factor C1 Homo sapiens 56-61 8364925-2 1993 The significance of such variation has been assessed by monitoring molecular and cellular processes induced by etoposide (VP-16) in the human lymphoblastoid T-cell lines CCRF-CEM (CEM) and MOLT-4 contrasted, where appropriate, with those induced by necrotizing injury. Etoposide 111-120 host cell factor C1 Homo sapiens 122-127 8362689-5 1993 Three courses of salvage chemotherapy of VP-16 (etoposide) were performed. Etoposide 48-57 host cell factor C1 Homo sapiens 41-46 8344765-2 1993 The patient was treated with cisplatin, bleomycin, and etoposide (VP-16) combination chemotherapy. Etoposide 55-64 host cell factor C1 Homo sapiens 66-71 8467452-4 1993 The combination of CDDP and etoposide (VP-16) has shown synergistic activity in other settings. Etoposide 28-37 host cell factor C1 Homo sapiens 39-44 8514100-0 1993 [The value of etoposide (VP-16) in the therapy of refractory ovarian cancer]. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 7694118-0 1993 Hypersensitivity of lymphoblastoid lines derived from ataxia telangiectasia patients to the induction of chromosomal aberrations by etoposide (VP-16). Etoposide 132-141 host cell factor C1 Homo sapiens 143-148 7694118-1 1993 Mammalian DNA topoisomerase II represents the cellular target of many antitumor drugs, such as epipodophyllotoxin VP-16 (etoposide). Etoposide 121-130 host cell factor C1 Homo sapiens 114-119 8398708-1 1993 BACKGROUND: We attempted to determine the maximum tolerated dose and toxicity of etoposide (VP-16) when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the intraperitoneal (IP) route. Etoposide 81-90 host cell factor C1 Homo sapiens 92-97 8394080-2 1993 Using alkaline elution assays, ICRF-187 in a dose-dependent manner inhibited the formation of DNA single strand breaks (SSBs) as well as DNA-protein cross-links induced by drugs such as VP-16 (etoposide), m-AMSA [4"-(9-acridinylamino)-methanesulfon-m-anisidide], daunorubicin and doxorubicin (Adriamycin) which are known to stimulate DNA-topoisomerase II cleavable complex formation. Etoposide 193-202 host cell factor C1 Homo sapiens 186-191 8411740-2 1993 Combination chemotherapy, including etoposide (VP-16) and tegafur (FT) allowed the patient to survive for approximately a year after the onset of the initial symptoms. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 8097746-1 1993 The topoisomerase II inhibitor, VP-16 (etoposide), is an important component in many chemotherapeutic regimens. Etoposide 39-48 host cell factor C1 Homo sapiens 32-37 8395599-2 1993 Thirty-six compounds that completely inhibited enzyme activity at a concentration of 500 nM or less, as assessed by ATP-dependent unknotting of P4 phage DNA, were at least 100-fold more potent than the clinically useful antitumor agent etoposide (VP-16). Etoposide 236-245 host cell factor C1 Homo sapiens 247-252 8483318-4 1993 The DNA topoisomerase inhibitors mitoxantrone, VP-16 (etoposide), and m-AMSA (amsacrine) were more effective in inducing DNA breaks than was hydroxyurea or cytosine arabinoside (AraC). Etoposide 54-63 host cell factor C1 Homo sapiens 47-52 8471659-7 1993 These drugs, together with etoposide (VP-16) had been found to be very effective in relapsed cases [7]. Etoposide 27-36 host cell factor C1 Homo sapiens 38-43 8503273-1 1993 A case of a girl with Langerhans cell histiocytosis who had hypofibrinogenemia during etoposide (VP-16) and prednisolone therapy is described. Etoposide 86-95 host cell factor C1 Homo sapiens 97-102 8382554-1 1993 Type II DNA topoisomerase breaks both DNA strands, and many anticancer agents including etoposide (VP-16) and teniposide (VM-26) have been developed by targeting topoisomerase II molecules. Etoposide 88-97 host cell factor C1 Homo sapiens 99-104 8447565-0 1993 High frequency of etoposide (VP-16)-related secondary leukemia in children with non-Hodgkin"s lymphoma. Etoposide 18-27 host cell factor C1 Homo sapiens 29-34 8426196-1 1993 PURPOSE: To describe the occurrence of secondary acute myeloid leukemia (AML) in children with acute lymphoblastic leukemia (ALL) treated with etoposide (VP-16). Etoposide 143-152 host cell factor C1 Homo sapiens 154-159 8509818-1 1993 12 patients: (7 males and 5 females) with recurrent brainstem gliomas were treated with the oral topoisomerase inhibitor VP-16 (Etoposide). Etoposide 128-137 host cell factor C1 Homo sapiens 121-126 7681619-0 1993 Prognosis of intracranial germ cell tumours: effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16). Etoposide 94-103 host cell factor C1 Homo sapiens 105-119 7681619-1 1993 A co-operative study for patients with intracranial germ cell tumours was performed to analyze their prognosis and the effectiveness of Cisplatin/Etoposide (CDDP/VP-16) chemotherapy. Etoposide 146-155 host cell factor C1 Homo sapiens 157-167 8168727-0 1993 Tyrosinase-induced phenoxyl radicals of etoposide (VP-16): interaction with reductants in model systems, K562 leukemic cell and nuclear homogenates. Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 8168727-1 1993 Etoposide (VP-16) is an antitumor drug currently in use for the treatment of a number of human cancers. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 1358264-8 1992 In the manner evaluated, taxol plus either adriamycin, cisplatin, cyclophosphamide or etoposide (VP-16) were not meaningfully more efficacious than the more effective drug in each of those combination settings. Etoposide 86-95 host cell factor C1 Homo sapiens 97-102 1492228-0 1992 High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies. Etoposide 10-19 host cell factor C1 Homo sapiens 21-26 1432038-0 1992 Chemotherapy with vincristine (VCR) and etoposide (VP-16) in children with low-grade astrocytoma. Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 1403039-1 1992 PURPOSE: A phase II study of etoposide (VP 16) and carboplatin (CBDCA) was performed in patients with metastatic neuroblastoma (NB). Etoposide 29-38 host cell factor C1 Homo sapiens 40-45 1514527-2 1992 Thirty-five patients were entered in a Phase I trial of an admixture infusion of etoposide (VP-16) and carboplatin (CBDCA) administered continuously for 5 or 7 days. Etoposide 81-90 host cell factor C1 Homo sapiens 92-97 1421436-2 1992 Surviving populations generated sublines designated DXR-10 which expressed significant resistance to etoposide (VP-16) and vincristine (VCR), but not to adriamycin (ADR) or acute X-irradiation, as judged by clonogenic assays. Etoposide 101-110 host cell factor C1 Homo sapiens 112-117 1534319-0 1992 Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 1377186-0 1992 Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 1318951-1 1992 PURPOSE: A phase II study that used combination chemotherapy with carboplatin (CBDCA) and etoposide (VP 16) (CE) was performed on patients with recurrent malignant glioma to investigate tumor control and toxicity. Etoposide 90-99 host cell factor C1 Homo sapiens 101-106 1515884-1 1992 Thirty-seven patients with advanced hematologic malignancy were entered into a phase I study designed to define a maximum tolerable dose (MTD) of etoposide (VP-16) and cyclophosphamide (CY) combined with 12 Gy fractionated total body irradiation (TBI) as preparation for marrow transplantation from an HLA-identical sibling (n = 13) or with cryopreserved autologous marrow (n = 24). Etoposide 146-155 host cell factor C1 Homo sapiens 157-162 1525405-0 1992 Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures. Etoposide 12-21 host cell factor C1 Homo sapiens 23-28 21584513-3 1992 Exposure to inhibitors of DNA topoisomerase I (camptothecin: CPT-11) and II (etoposide: VP-16 and teniposide: VM-26) could efficiently induce CAT activities in both time- and dose-dependent manners. Etoposide 77-86 host cell factor C1 Homo sapiens 88-93 1581902-2 1992 The epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) are usually included among the drugs recognized by this MDR phenotype, and the MDR EHR2/DNR cell line is greater than 50-fold cross-resistant to VP-16. Etoposide 35-44 host cell factor C1 Homo sapiens 46-51 1534319-1 1992 Cyclosporin A reverses multidrug resistance (MDR) and increases the in vivo cytostatic activity and toxicity of the anticancer agent etoposide (VP 16-213). Etoposide 133-142 host cell factor C1 Homo sapiens 144-149 1611612-2 1992 Combination chemotherapy with cisplatin (CDDP) and etoposide (VP-16) was given to five children with early recurrent medulloblastoma. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 1346631-7 1992 The resistant lines were cross-resistant to VP-16 (etoposide), despite lack of previous exposure to this drug. Etoposide 51-60 host cell factor C1 Homo sapiens 44-49 1768975-5 1991 Univariate analysis identified the following risk factors for neurotoxicity: use of unrelated or HLA-mismatched related donors, administration of etoposide (VP-16) or total body irradiation as part of conditioning, use of corticosteroids for prophylaxis or treatment of acute GVHD, or development of either acute GVHD or clinically significant microangiopathic hemolytic anemia (MAHA) post-BMT. Etoposide 146-155 host cell factor C1 Homo sapiens 157-162 1663216-0 1991 [Complete remission of a highly malignant, progressive under therapy Wilm"s tumor using the combination carboplatin and etoposide (VP 16)]. Etoposide 120-129 host cell factor C1 Homo sapiens 131-136 1722410-1 1991 The possibility of increasing the activity of etoposide (VP-16) by combining this anti-cancer agent with indomethacin (Indo) was investigated by treating murine and human cultured tumor cells with a combination of Indo and VP-16 and quantitating VP-16 cytotoxicity by the [3H]thymidine incorporation assay. Etoposide 46-55 host cell factor C1 Homo sapiens 57-62 1310581-2 1992 In this study, we further show that in addition to m-AMSA and VM26 which we had previously reported, a widely used and clinically available drug, etoposide (VP-16 or VePesid) can irreversibly inhibit CMV replication at the drug concentration (2.5 micrograms/ml) greatly below toxic levels to stationary phase cells. Etoposide 146-155 host cell factor C1 Homo sapiens 157-173 1310581-5 1992 Because of their irreversible inhibitory effects and approval usage in clinical oncology, it is suggested that this group of compounds, particularly etoposide (VP-16), can be used to control life-threatening CMV infections, such as CMV pneumonitis and CMV retinitis, in cancer and immunocompromised patients or patients with AIDS. Etoposide 149-158 host cell factor C1 Homo sapiens 160-165 1758445-1 1991 Podophyllotoxin (PD) and its derivative etoposide (VP-16), a clinically useful anticancer drug, exhibit different mechanisms of action. Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 1779456-2 1991 In this report we investigated pharmacokinetics of enositabine (BHAC), arabinosylcytosine (Ara-C) and etoposide (VP-16) in a patient on maintenance hemodialysis who suffered from acute myelomonocytic leukemia and treated by BHAC-EV regimen. Etoposide 102-111 host cell factor C1 Homo sapiens 113-118 1764166-0 1991 Synthesis and biological activity of galactopyranoside derivatives of 4"-demethylepipodophyllotoxin showing VP-16 (etoposide)-like activity. Etoposide 115-124 host cell factor C1 Homo sapiens 108-113 1743556-0 1991 Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 1741774-5 1991 Exposure of MCF-7 cells to etoposide (VP-16), mitoxantrone and camptothecin resulted in the detection of significant amounts of protein-linked DNA breaks, whereas none were found in MD-treated cells. Etoposide 27-36 host cell factor C1 Homo sapiens 38-43 1955738-2 1991 In this study, we describe the effects of methylprednisolone (MP) and etoposide (VP16) alone or in combination on 5 tumor cell lines (HL-60, a promyelocytic cell line; Molt-4, a T cell leukemia; Daudi, a Burkitt"s lymphoma and R10/8226 and R40/8226, doxorubicin-resistant myeloma cell lines). Etoposide 70-79 host cell factor C1 Homo sapiens 81-85 1651994-1 1991 A randomized study comparing teniposide (VM-26) and etoposide (VP-16) was performed to investigate whether there are any differences in the activity and toxicity of these two analogs in small-cell lung cancer (SCLC). Etoposide 52-61 host cell factor C1 Homo sapiens 63-68 1654205-2 1991 In order to see whether ICRF-154 and ICRF-193 affect cellular topoisomerase II in situ or not, we examined the effect of these drugs on etoposide (VP-16)-induced, topoisomerase II-mediated DNA breaks in RPMI 8402 cells by alkaline sedimentation analysis. Etoposide 136-145 host cell factor C1 Homo sapiens 147-152 1655218-1 1991 Encouraging response rates have been reported in Stage III non-small cell lung cancer when 5-fluorouracil (5-FU), etoposide (VP-16), and cisplatin (FED) have been combined with radiation therapy (RT) or RT and surgery. Etoposide 114-123 host cell factor C1 Homo sapiens 125-130 1849124-1 1991 Etoposide (VP-16) resistance is expressed following in vitro exposure of HN-1 and MCF-7 human tumor cells to the drug itself or to fractionated X irradiation. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 1920837-0 1991 [Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia]. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 1645864-3 1991 Protein associated dsb were introduced by treating cells with the DNA topoisomerase II poison; etoposide (VP-16). Etoposide 95-104 host cell factor C1 Homo sapiens 106-111 1849785-4 1991 Responding patients received consolidation therapy with cisplatin and etoposide (VP-16). Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 1673356-8 1991 The addition of the cytotoxic agent etoposide (VP-16) following antibody purging results in a 4.6 log reduction of malignant cells. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 1717863-0 1991 Complete remission of metastatic teratoma from malignant testicular tumor using salvage chemotherapy with VP-16 (etoposide), CDDP, and ACNU--case report. Etoposide 113-122 host cell factor C1 Homo sapiens 106-111 1920837-1 1991 We investigated the efficacy of oral etoposide (VP-16) for the patients with acute non-lymphocytic leukemia (ANLL) in relapse or refractory to the standard chemotherapy. Etoposide 37-46 host cell factor C1 Homo sapiens 48-53 1648924-2 1991 Although the stabilization of topoisomerase II cleavable complexes by etoposide (VP-16) has been recognized to be important for cell killing, the lethal events following the formation of cleavable complexes remain to be elucidated. Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 1827357-2 1991 Successful control of clinical symptoms and eosinophil counts was obtained with etoposide (VP16-213) for 18 months. Etoposide 80-89 host cell factor C1 Homo sapiens 91-95 2026183-1 1991 Ten patients with non-Hodgkin"s lymphoma (NHL) and nine with Hodgkin"s Disease (HD) received high-dose busulfan and etoposide (VP-16) prior to autologous bone marrow transplantation (ABMT). Etoposide 116-125 host cell factor C1 Homo sapiens 127-132 2066761-1 1991 We conducted a phase II study of intraperitoneal (IP) cisplatin (CDDP) and etoposide (VP-16) as salvage therapy in patients with ovarian cancer who had persistent disease or who had relapsed after primary systemic chemotherapy and had residual disease of less than 2 cm. Etoposide 75-84 host cell factor C1 Homo sapiens 86-91 2015041-2 1991 We further determined whether NK-250 and NK-252 among the six compounds could potentiate cytocidal activities of etoposide (VP16) as well as VCR against both multidrug-resistant (MDR) cell line (VJ-300) and atypical MDR cell line (KB/VM-4). Etoposide 113-122 host cell factor C1 Homo sapiens 124-128 1824825-1 1991 To investigate the possibility that anticancer drugs combined with cytokines may show increased activity, human tumor cells were treated with combinations of human recombinant interleukin 1 alpha (rIL-1 alpha) and etoposide (VP-16). Etoposide 214-223 host cell factor C1 Homo sapiens 225-230 1991703-0 1991 Activity of etoposide (VP-16) in human tumor cells under different growth conditions. Etoposide 12-21 host cell factor C1 Homo sapiens 23-28 1991703-1 1991 The effect of etoposide (VP-16) on a human epidermoid carcinoma cell line (HEp3) has been evaluated under different growth conditions. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 1646050-2 1991 The patients were treated with one or two courses of high dose carboplatin (CBDCA) and etoposide (VP-16) plus ifosfamide (IFX) with mesna uroprotection and autologous bone marrow support. Etoposide 87-96 host cell factor C1 Homo sapiens 98-103 1781917-0 1991 Chemical compatibility of mitoxantrone and etoposide (VP-16). Etoposide 43-52 host cell factor C1 Homo sapiens 54-59 1984829-1 1991 Etoposide (VP16-213, NSC 141540) induces a complete response (CR) in 15% to 25% of previously treated patients with acute nonlymphocytic leukemia (ANLL) when used as a single agent. Etoposide 0-9 host cell factor C1 Homo sapiens 11-15 1984831-1 1991 The epipodophyllotoxin derivative etoposide (VP-16) has been in widespread use both alone and in combination chemotherapy for the past decade. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 2174464-1 1990 In an effort to test clinically the hypothesis that the duration of cellular exposure to etoposide (VP-16) and cisplatin (CDDP) is an important determinant of cytotoxicity, we performed a phase III randomized trial comparing an outpatient bolus regimen of combined VP-16 and CDDP with a sequential infusion over 72 hours of these same two drugs. Etoposide 89-98 host cell factor C1 Homo sapiens 100-105 2007774-0 1991 Etoposide (VP 16-213) induced hepatitis. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2007774-2 1991 Acute hepatitis is a potential, although rare, complication following administration of high doses of Etoposide (VP 16-213). Etoposide 102-111 host cell factor C1 Homo sapiens 113-118 1702148-1 1991 This is a Southwest Oncology Group (SWOG) prospective randomized trial of cisplatin, vinblastine, and bleomycin (PVB) versus vinblastine, cisplatin, and etoposide (VP-16) (VPV) in the treatment of advanced germ cell tumors of the testis. Etoposide 153-162 host cell factor C1 Homo sapiens 164-169 2016905-1 1991 Sodium-dependent amino acid transport of methylaminoisobutyric acid (MeAIB) in a human myelogenous leukemic cell line K562 was inhibited by 30 nM etoposide (VP-16). Etoposide 146-155 host cell factor C1 Homo sapiens 157-162 1979245-3 1990 The drug-resistant variants were resistant to vinblastine (VBL), colchicine (COL), and etoposide (VP-16) in the order VBL greater than COL greater than VP-16 on the basis of 50% inhibitory concentration values obtained by clonogenic assay with continuous drug exposure. Etoposide 87-96 host cell factor C1 Homo sapiens 98-103 1979245-3 1990 The drug-resistant variants were resistant to vinblastine (VBL), colchicine (COL), and etoposide (VP-16) in the order VBL greater than COL greater than VP-16 on the basis of 50% inhibitory concentration values obtained by clonogenic assay with continuous drug exposure. Etoposide 87-96 host cell factor C1 Homo sapiens 152-157 2226679-0 1990 Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 2226679-1 1990 We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal human bone marrow; two human leukemia cell lines, K562 and CEM; their MDR variants, K562/DOX and CEM/VLB; and mixtures of normal marrow and leukemic cells. Etoposide 123-132 host cell factor C1 Homo sapiens 134-139 1700077-10 1990 In 1978, we initiated salvage therapy with cisplatin plus etoposide (VP-16) in patients not cured with PVB, and 25% of these patients were subsequently cured with this regimen. Etoposide 58-67 host cell factor C1 Homo sapiens 69-74 2228309-0 1990 Chromosome aberrations induced by etoposide (VP-16) are not random. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 2364367-11 1990 Cisplatin and etoposide (VP-16) appeared to be the most active chemotherapeutic agents. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 2287079-0 1990 [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia]. Etoposide 43-52 host cell factor C1 Homo sapiens 54-59 2135392-5 1990 The dose-response curve of GP-7 on SGC-7901 cell was similar to that of etoposide (VP-16). Etoposide 72-81 host cell factor C1 Homo sapiens 83-88 2387345-1 1990 We studied the effects of two modulators of multidrug resistance (MDR), cyclosporine and verapamil, on the cytotoxicity of etoposide (VP-16) in normal bone marrow cells. Etoposide 123-132 host cell factor C1 Homo sapiens 134-139 2263514-3 1990 The major advances in single-agent antineoplastic drug therapy include the introduction of cisplatin almost 20 years ago and of etoposide (VP-16) in the mid-1980s. Etoposide 128-137 host cell factor C1 Homo sapiens 139-144 2262732-1 1990 The survival of cultured HeLa S3 cells and their progression through the cell cycle after exposure to Etoposide (VP-16) were studied. Etoposide 102-111 host cell factor C1 Homo sapiens 113-118 2386890-1 1990 The authors administered high-dose chemotherapy with cyclophosphamide, BCNU (carmustine) and VP-16 (etoposide) plus autologous bone marrow transplantation (ABMT) to 22 adult patients with relapsed acute leukemia in second or subsequent remission. Etoposide 100-109 host cell factor C1 Homo sapiens 93-98 2389968-1 1990 In order to deliver a high concentration of anti-cancer drugs in tumor tissue, preoperative intra-arterial injection therapy using Etoposide (VP-16), Pirarubicin (THP-ADM) and Cisplatin (CDDP), was used for 22 patients with resectable advanced gastric cancer. Etoposide 131-140 host cell factor C1 Homo sapiens 142-147 2297654-1 1990 A Phase II study of the combination of etoposide (VP-16) and cyclophosphamide (CPM) was conducted in an attempt to identify active and potentially less toxic agents for treating patients with osteogenic sarcoma (OS). Etoposide 39-48 host cell factor C1 Homo sapiens 50-55 2316488-1 1990 Sixteen patients with hepatic metastases of histologically documented breast cancer were treated with etoposide (VP 16-213) and cyclophosphamide. Etoposide 102-111 host cell factor C1 Homo sapiens 113-118 2313334-1 1990 Cyclophosphamide, carmustine (BCNU), and etoposide (VP-16) (CBV) is a widely used conditioning regimen in autologous bone marrow transplantation (ABMT) of patients with refractory and relapsed lymphoma. Etoposide 41-50 host cell factor C1 Homo sapiens 52-57 2314118-1 1990 Diaziquone (AZQ) and etoposide (VP-16) were administered as simultaneous 5-day continuous infusions to 27 patients with acute leukemia (22 with acute myeloid leukemia (AML), three with chronic myeloid leukemia in blast crisis (CML-B), and two with acute lymphocytic leukemia) at four different doses in a phase I trial. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 2156515-1 1990 Etoposide (VP-16) and several other unrelated anti-tumour agents appear to act by inhibiting the enzyme DNA topoisomerase II. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2157554-3 1990 In our phase II pilot studies with cisplatin (CDDP) and etoposide (VP-16), we observed a 26% response rate; with CDDP, VP-16, and mitomycin-C, a 38% response rate was obtained in advanced NSCLC patients. Etoposide 56-65 host cell factor C1 Homo sapiens 67-72 2302390-8 1990 Etoposide (VP-16) at concentrations up to 10 mol% did not compete with [3H]VM-26 for association with dioleoyl-PC. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2297586-1 1990 The inhibitory effects of mafosfamide lysine, ASTA-Z 7654 (ASTA-Z) and etoposide, (VP16-213) on human leukemic progenitor cells (AML-CFU) were studied using a clonogenic assay. Etoposide 71-80 host cell factor C1 Homo sapiens 83-87 2297632-2 1990 A prospective clinical trial was done to evaluate the efficacy and toxicity of cisplatin plus etoposide (VP-16) in patients with breast cancer who failed one previous chemotherapy regimen for advanced disease or relapsed within 12 months of adjuvant chemotherapy. Etoposide 94-103 host cell factor C1 Homo sapiens 105-110 1976450-1 1990 We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16. Etoposide 18-27 host cell factor C1 Homo sapiens 29-34 1976450-1 1990 We established an etoposide (VP-16)-resistant human small-cell lung cancer cell line (H69/VP) by stepwise exposure to VP-16. Etoposide 18-27 host cell factor C1 Homo sapiens 118-123 2189591-1 1990 The pharmacology, toxicity, and therapeutic effectiveness of etoposide (VP-16) given by the intrapleural route were examined in a phase I trial. Etoposide 61-70 host cell factor C1 Homo sapiens 72-77 2295904-1 1990 We conducted a phase II trial of intraperitoneal (IP) cisplatin (DDP) and etoposide (VP-16) in stage III and IV newly diagnosed ovarian carcinoma patients with residual disease of any size. Etoposide 74-83 host cell factor C1 Homo sapiens 85-90 34243013-1 2021 Etoposide is a semi-synthetic glycoside derivative of podophyllotoxin, also known as VP-16. Etoposide 0-9 host cell factor C1 Homo sapiens 85-90 2300386-1 1990 The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion. Etoposide 24-33 host cell factor C1 Homo sapiens 35-40 3813490-1 1986 Ten patients with neuroblastoma were treated with a standard pulsed administration schedule of cis-platinum and etoposide (VP16-213). Etoposide 112-121 host cell factor C1 Homo sapiens 123-127 6325855-0 1984 Etoposide (VP 16-213; VePesid). Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 34757813-1 2021 It is hypothesized that L-arginine (ARG) can improve etoposide (VP-16) water solubility while preserving its anticancer activity. Etoposide 53-62 host cell factor C1 Homo sapiens 64-69 34813380-1 2021 It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity. Etoposide 24-33 host cell factor C1 Homo sapiens 34-39 34813380-1 2021 It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity. Etoposide 24-33 host cell factor C1 Homo sapiens 66-71 2294193-2 1990 A vincristine (VCR)-resistant glioma cell line showed a cross resistance to Adriamycin (doxorubicin, ADR) and etoposide (VP-16) to varying extents, suggesting the presence of MDR; the resistance to VCR was considerably decreased by calcium entry blockers. Etoposide 110-119 host cell factor C1 Homo sapiens 121-126 26540186-3 2015 We have previously shown that NO plays a significant role in the detoxification of etoposide (VP-16), a topoisomerase II poison in vitro and in human melanoma cells. Etoposide 84-93 host cell factor C1 Homo sapiens 95-100 8656261-2 1996 Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16. Etoposide 154-163 host cell factor C1 Homo sapiens 165-170 8656261-2 1996 Here, we report on seven patients with recurrent medulloblastoma, most heavily pretreated with a variety of chemotherapeutic agents, including parenteral etoposide (VP-16), who showed responses to the administration of repeated courses of low-dose oral VP-16. Etoposide 154-163 host cell factor C1 Homo sapiens 253-258 34813380-1 2021 It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity. Etoposide 160-169 host cell factor C1 Homo sapiens 34-39 34813380-1 2021 It is hypothesized that etoposide/VP-16 nanomicellar formulation (VP-16 NMF) utilizing D-alpha-Tocopherol polyethylene glycol 1000 succinate (TPGS) can improve etoposide solubility and anticancer activity. Etoposide 160-169 host cell factor C1 Homo sapiens 66-71 34813380-3 2021 Among these four formulations, 10 wt% of TPGS loaded with VP-16 NMF dramatically enhanced etoposide apparent solubility by 26-folds compared with the native drug. Etoposide 90-99 host cell factor C1 Homo sapiens 58-63 34813380-8 2021 LC-MS/MS data showed a threefold increase in cellular uptake of VP-16 NMF in MCF-7 cell line compared with the native etoposide. Etoposide 118-127 host cell factor C1 Homo sapiens 64-69 34333949-5 2021 According to whether or not etoposide (VP-16) was included in the initial therapy, patients were divided into group 1 (VP-16 was not administrated in the initial treatment, n=31) and group 2 (the initial treatment included etoposide, n=12). Etoposide 28-37 host cell factor C1 Homo sapiens 39-44 2753092-0 1989 Comparison of in vitro inhibition of etoposide (VP16) on leukemic and normal myeloid, erythroid clonogenic cells. Etoposide 37-46 host cell factor C1 Homo sapiens 48-52 35261636-3 2022 However, whether HGF has any effect on apoptosis induced by VP-16 (etoposide) in CML cells and its underlying mechanisms are unclear. Etoposide 67-76 host cell factor C1 Homo sapiens 60-65 2477515-7 1989 She was treated with etoposide (VP-16), high-dose cisplatin, vinblastine, and bleomycin and is currently without evidence of disease 46 months postmetastasis. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 2545335-1 1989 Dipyridamole (DPM) enhanced the sensitivity of human ovarian carcinoma 2008 cells to etoposide (VP-16) producing a 5.5-fold reduction in 50% inhibitory concentration at a DPM concentration of 20 microM. Etoposide 85-94 host cell factor C1 Homo sapiens 96-101 2746758-3 1989 Moreover etoposide (VP-16) and hyperthermia at relatively low temperature enhanced the antitumor effect of rTNF-S. Etoposide 9-18 host cell factor C1 Homo sapiens 20-25 35097256-1 2022 Etoposide (VP-16) is used for the treatment of various cancers, including nasopharyngeal carcinoma (NPC); however, cancers develop resistance to this agent by promoting DNA repair. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2593167-1 1989 To investigate the possibility of increased activity of cytotoxic anticancer drugs combined with cytokines, we treated human melanoma cells with combinations of etoposide (VP-16) and human recombinant interleukin-1 alpha (rIL-1 alpha). Etoposide 161-170 host cell factor C1 Homo sapiens 172-177 2556011-2 1989 Following the development of bone metastases, further chemotherapy with etoposide (VP-16) and cis-platinum was not successful and the patient"s condition was rapidly fatal. Etoposide 72-81 host cell factor C1 Homo sapiens 83-88 2589229-1 1989 Twenty-two patients with metastatic colorectal carcinoma were treated in a Phase I-II study of combination therapy with 5-fluorouracil (5-FU) and etoposide (VP-16). Etoposide 146-155 host cell factor C1 Homo sapiens 157-162 2697195-4 1989 The outcome was invariably fatal before the use of etoposide (VP 16) in association with steroids and intrathecal methotrexate. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 2753092-1 1989 We have compared in various clonogenic assays the in vitro sensitivity to etoposide (VP16) of 1) human leukemic precursors (leukemia colony-forming units; L-CFU), 2) normal erythroid progenitors (erythroid burst-forming units; BFU-E, and 3) normal committed myeloid progenitors (granulocyte-macrophage colony-forming units; CFU-GM and more primitive hemopoietic precursors (PPC) that adhere to cultured marrow stromal cells. Etoposide 74-83 host cell factor C1 Homo sapiens 85-89 2733097-4 1989 Recombinant human tumor necrosis factor (rTNF) and VP16 (etoposide), both well known cytotoxic and cytostatic anticancer agents, were tested singly and in combination against this metastatic model of human renal adenocarcinoma. Etoposide 57-66 host cell factor C1 Homo sapiens 51-55 2624125-1 1989 Podophyllic acid piperidyl hydrazone nitroxide radical (GP-1) and etoposide (VP-16), derivatives of podophyllotoxin, inhibited DNA, RNA, protein and ATP synthesis of leukemia L7712 cells at a concentration of 5 micrograms/ml. Etoposide 66-75 host cell factor C1 Homo sapiens 77-82 2564628-1 1989 In order to study the mechanism of etoposide (VP-16) resistance in human tumor cells and to assess the role of P-170 glycoprotein in VP-16 accumulation, we have examined the uptake and efflux of VP-16 in both sensitive and multidrug-resistant MCF-7 human breast and HL60 human promyelocytic leukemia cells. Etoposide 35-44 host cell factor C1 Homo sapiens 46-51 2914288-2 1989 The compatibility of etoposide (VP-16-213) and cisplatin (CDDP) in an admixture solution was established by High Pressure Liquid Chromatography (HPLC) studies in vitro at room temperature. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 2918334-1 1989 In this phase I study, we administered etoposide (VP-16) orally for 21 consecutive days to patients with advanced refractory cancers. Etoposide 39-48 host cell factor C1 Homo sapiens 50-55 2727988-0 1989 Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line. Etoposide 20-29 host cell factor C1 Homo sapiens 31-36 2536584-0 1989 Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. Etoposide 14-23 host cell factor C1 Homo sapiens 25-30 2734645-2 1989 Etoposide (VP-16) administered intraperitoneally as part of a phase I trial produced dramatic relief of the obstruction. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2548593-0 1989 Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. Etoposide 63-72 host cell factor C1 Homo sapiens 74-79 2540199-3 1989 The network production is abolished by omission of ATP, strongly inhibited by etoposide (VP-16), but only slightly inhibited by antibody to topoisomerase I, indicating that the major enzyme responsible for catenation is DNA topoisomerase II. Etoposide 78-87 host cell factor C1 Homo sapiens 89-94 2543340-6 1989 A second trial was undertaken in which etoposide (VP-16) was added because of its synergism with cisplatin. Etoposide 39-48 host cell factor C1 Homo sapiens 50-55 2539902-1 1989 Our human T-cell leukemia line, CEM/VM-1, selected for resistance to VM-26 (teniposide), is cross-resistant to several drugs that interact with topoisomerase II, including VP-16 (etoposide), 4"-(9-acridinylamino)methanesulphon-m-anisidide, daunorubicin, and mitoxantrone. Etoposide 179-188 host cell factor C1 Homo sapiens 172-177 2539716-1 1989 Although the etoposide (VP-16) and cisplatin combination has shown therapeutic activity in lung cancer, human results to date have not matched the expectation of synergism raised by animal model studies. Etoposide 13-22 host cell factor C1 Homo sapiens 24-29 2563654-2 1989 C25X cells were cross-resistant to daunomycin and etoposide (VP-16) but not to vincristine or colchicine. Etoposide 50-59 host cell factor C1 Homo sapiens 61-66 2702985-0 1989 Etoposide (VP-16) uptake by tumour spheroids and activity in the presence of Brij 30, formulation additives and sodium salicylate. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2609973-1 1989 The interaction of the anticancer drug, etoposide (VP16-213), with DPPC bilayer vesicles was investigated by DSC and Laser Raman techniques. Etoposide 40-49 host cell factor C1 Homo sapiens 51-55 2620246-5 1989 Etoposide (VP-16), at 100 microM produced 3-3.5 log inhibition of ES cell lines and complete inhibition of CFU-GM growth. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2513840-4 1989 The cytostatic agent etoposide (VP-16) was able to augment the hCG secretion on the choriocarcinoma cells but did not alter its production on term placenta. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 3133101-0 1988 Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. Etoposide 57-66 host cell factor C1 Homo sapiens 68-73 3056605-1 1988 Eighteen evaluable children with recurrent Langerhans" cell histiocytosis (LCH) which was resistant to standard therapy, were treated with etoposide (VP 16-213), 200 mg/m2/day for 3 days every 3 weeks, to study the efficacy and toxicity of this drug. Etoposide 139-148 host cell factor C1 Homo sapiens 150-155 2851175-3 1988 The small cell lung cancer (SCLC) lines were generally more sensitive than the non-small cell lung cancer (NSCLC) lines to vincristine, thiotepa, and etoposide (VP-16). Etoposide 150-159 host cell factor C1 Homo sapiens 161-166 2851179-1 1988 A multicenter Italian Cooperative Study Group (FONICAP) conducted a prospective, randomized trial comparing cisplatin and etoposide (VP-16) with single-agent etoposide. Etoposide 122-131 host cell factor C1 Homo sapiens 133-138 2851179-4 1988 The overall response rates for the etoposide group and cisplatin/etoposide (VP-16) group were 7% and 26%, respectively (P less than 0.005). Etoposide 65-74 host cell factor C1 Homo sapiens 76-81 2851180-6 1988 In summary, combination chemotherapy using cisplatin and etoposide (VP-16) appears to be the most active and safest regimen in NSCLC. Etoposide 57-66 host cell factor C1 Homo sapiens 68-73 2844393-1 1988 The alkaloid derivative 4"-demethylepipodophyllotoxin 9-(4,6-O-ethylidene)-beta-D-glucopyranoside (etoposide, VP-16) is believed to exert cytotoxicity by causing double-stranded DNA breaks through interruption of the breaking-resealing reaction of topoisomerase II (topo II). Etoposide 24-97 host cell factor C1 Homo sapiens 110-115 2844393-1 1988 The alkaloid derivative 4"-demethylepipodophyllotoxin 9-(4,6-O-ethylidene)-beta-D-glucopyranoside (etoposide, VP-16) is believed to exert cytotoxicity by causing double-stranded DNA breaks through interruption of the breaking-resealing reaction of topoisomerase II (topo II). Etoposide 99-108 host cell factor C1 Homo sapiens 110-115 3060442-3 1988 Treatment with high concentration of etoposide (VP-16) (10 to 80 micrograms/ml) resulted in a maximal depletion of 1.5 log, whereas more efficient tumor cell eradication (2.5 log) was achieved by 30-min incubation with 100 micrograms/ml4HC. Etoposide 37-46 host cell factor C1 Homo sapiens 48-53 2842045-0 1988 DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Etoposide 30-39 host cell factor C1 Homo sapiens 41-46 2842045-1 1988 Pleotropic resistant human breast cancer cells (MCF-7), selected for resistance to Adriamycin, were used to study the production of DNA strand breaks by etoposide (VP-16) and its relationship to drug cytotoxicity. Etoposide 153-162 host cell factor C1 Homo sapiens 164-169 2841844-0 1988 Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2839633-1 1988 In view of experimental and clinical data suggesting enhanced antiproliferative efficacy from a continuous infusion of etoposide (VP-16) concomitant with cisplatin (CDDP), we performed a dose-seeking study of a five-day infusion of VP-16, 30 mg/m2/24 h and CDDP, 18.5 to 25 mg/m2/24 h. Among eight patients with advanced solid tumors, dose-limiting toxicities were leukopenia and thrombocytopenia. Etoposide 119-128 host cell factor C1 Homo sapiens 130-135 2839633-1 1988 In view of experimental and clinical data suggesting enhanced antiproliferative efficacy from a continuous infusion of etoposide (VP-16) concomitant with cisplatin (CDDP), we performed a dose-seeking study of a five-day infusion of VP-16, 30 mg/m2/24 h and CDDP, 18.5 to 25 mg/m2/24 h. Among eight patients with advanced solid tumors, dose-limiting toxicities were leukopenia and thrombocytopenia. Etoposide 119-128 host cell factor C1 Homo sapiens 232-237 3292713-2 1988 Fifty-eight patients (85%) entered complete remission after treatment with etoposide (VP-16)/cytarabine (ara-C) (A), followed by daunorubicin (Dauno)/ara-C/thioguanine (6-TG) (B) and then VP-16/azacytidine (5-AZ) (C). Etoposide 75-84 host cell factor C1 Homo sapiens 86-91 3044803-1 1988 We conducted a phase I trial with the combination carboplatin (CBDCA)-etoposide (VP-16) in thoracic cancer. Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 3133101-2 1988 Twenty-one patients with refractory germ cell tumors were treated with a chemotherapy regimen containing etoposide (VP-16) (V) 75 mg/m2/day (days 1 to 5), ifosfamide (I) 3 g/m2/day (days 1 and 2) with a 3.6 g/m2 continuous infusion of mesna (days 1 and 2), and high-dose cisplatin (hP) 40 mg/m2/day (days 1 to 5). Etoposide 105-114 host cell factor C1 Homo sapiens 116-121 3410665-0 1988 Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. Etoposide 18-27 host cell factor C1 Homo sapiens 29-34 3282425-0 1988 Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3282425-1 1988 Twenty-six patients with advanced adenocarcinoma of the pancreas were treated with etoposide (VP-16), 100-180 mg/m2 i.v., days 1, 2, and 3, monthly. Etoposide 83-92 host cell factor C1 Homo sapiens 94-99 3410665-2 1988 Etoposide (VP-16), 150 mg/M2, given intravenously daily for 3 days every 3 weeks resulted in 3 complete responses and 6 partial responses in 154 patients with a spectrum of recurrent malignant solid tumors. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3305528-3 1987 The indications and side-effects of high dose methotrexate, ifosfamide and etoposide (VP-16) are summarized in tabular form. Etoposide 75-84 host cell factor C1 Homo sapiens 86-91 2449133-11 1988 Lately, VP-16 (etoposide) was found to be a useful salvage agent. Etoposide 15-24 host cell factor C1 Homo sapiens 8-13 3276544-0 1988 Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow. Etoposide 72-81 host cell factor C1 Homo sapiens 83-88 3276544-1 1988 In the present study we evaluated the effect of etoposide (VP-16-213) compared to mafosfamide-cyclohexylamine (Asta-Z 7654) on normal granulocyte-macrophage colony-forming unit (GM-CFU) growth, T-cell response to mitogens, and a clonogenic promyelocytic cell line (HL-60). Etoposide 48-57 host cell factor C1 Homo sapiens 59-64 3341784-7 1988 Recently, cisplatin, VP-16 (etoposide) and others are administered as trial use. Etoposide 28-37 host cell factor C1 Homo sapiens 21-26 3356201-0 1988 Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Etoposide 64-73 host cell factor C1 Homo sapiens 75-79 2855002-0 1988 Role of free radicals in etoposide (VP-16,213) action. Etoposide 25-34 host cell factor C1 Homo sapiens 36-41 2832457-1 1987 Etoposide (VP-16) is a semisynthetic podophyllotoxin derivative that is active against a number of solid and hematologic malignancies. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3502785-2 1987 A cyclophosphamide derivative (ASTA-Z 7654) and etoposide (VP16-213) have been tested on lymphoma and leukemia cell lines in a model that may represent a bone marrow situation in complete remission. Etoposide 48-57 host cell factor C1 Homo sapiens 59-63 3037127-3 1987 These drugs, such as adriamycin and etoposide (VP 16), are in widespread use in the treatment of human cancer. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 3037127-4 1987 The rTNF significantly enhanced the cytotoxic efficacy of the topoisomerase-targeted drugs actinomycin D, adriamycin, etoposide (VP 16) and teniposide (VM 26) against MBT-2 cells in vitro. Etoposide 118-127 host cell factor C1 Homo sapiens 129-134 2439659-1 1987 An intensive regimen of combined etoposide (VP-16) and 5-azacitidine (5-Az) was used to treat 96 children and adolescents with refractory or relapsed acute nonlymphocytic leukemia (ANLL). Etoposide 33-42 host cell factor C1 Homo sapiens 44-49 3613140-4 1987 The clinical stage was considered to be T3N2M1 (American joint committee (AJC) stage III M1), and his performance status was 4, so he was given etoposide (VP-16) alone as the initial chemotherapy treatment. Etoposide 144-153 host cell factor C1 Homo sapiens 155-160 3611870-0 1987 [Anticancer effect of VP16-213 (etoposide) on three choriocarcinoma cell lines]. Etoposide 32-41 host cell factor C1 Homo sapiens 22-26 3815383-1 1987 Etoposide (VP-16) is a semisynthetic epipodophyllotoxin that exhibits cell cycle phase specific cytotoxicity and enhanced effectiveness with increasing duration of drug exposure. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3829015-1 1987 Cisplatin (CPDD) and etoposide (VP-16) have activity as single agents in children with recurrent soft tissue sarcoma, with response rates approximating 20%. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 3469013-4 1987 Further, even though this cell line is approximately equal to 40-fold cross-resistant to the cytotoxic effect of etoposide (VP-16), it is similar to drug-sensitive CEM cells in the cellular pharmacology of [3H]VP-16 as determined by zero time binding, initial influx rate, steady state drug concentration, and unidirectional efflux. Etoposide 113-122 host cell factor C1 Homo sapiens 124-129 3027268-0 1987 Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. Etoposide 34-43 host cell factor C1 Homo sapiens 45-50 3581419-1 1987 Cytosine arabinoside (ara-C) and etoposide (VP-16) display synergy in the laboratory. Etoposide 33-42 host cell factor C1 Homo sapiens 44-49 3621455-0 1987 Drug monitoring of etoposide (VP16-213). Etoposide 19-28 host cell factor C1 Homo sapiens 30-34 3469424-0 1987 [Phase II study of etoposide (VP-16) in the form of intravenous injection for malignant lymphomas and acute leukemias: Hanshin Cooperative Study Group for Hematological Disorders]. Etoposide 19-28 host cell factor C1 Homo sapiens 30-35 3041238-1 1987 The two demethylepipodophyllotoxin glycosides, teniposide (VM-26) and etoposide (VP-16), have previously been reported to interact with DNA topoisomerase II by stabilizing a topoisomerase II-DNA covalent intermediate. Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 3756767-0 1986 Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Etoposide 70-79 host cell factor C1 Homo sapiens 81-86 3643849-0 1986 Pharmacokinetics of high dose etoposide (VP 16-213). Etoposide 30-39 host cell factor C1 Homo sapiens 41-46 3753024-0 1986 [Phase II study of etoposide (VP-16-213) in genitourinary tumors. Etoposide 19-28 host cell factor C1 Homo sapiens 30-35 2430876-6 1986 Also after treatment with Etoposide (VP-16), an increase of G2/M compartment was observed, and on the morphological manifestation enlarged nuclear cells or double-or multiple-nuclear cells were observed. Etoposide 26-35 host cell factor C1 Homo sapiens 37-42 3753024-2 1986 A co-operative phase II study of the semisynthetic podophyllotoxin derivative Etoposide (VP-16) was undertaken in patients with genitourinary tumors. Etoposide 78-87 host cell factor C1 Homo sapiens 89-94 3020707-0 1986 A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. Etoposide 51-60 host cell factor C1 Homo sapiens 62-67 3020753-2 1986 Here we describe a case with unresectable hepatocellular carcinoma who achieved a complete response and has survived for more than 2 years, following treatment with a combination of adriamycin and etoposide (VP 16-213). Etoposide 197-206 host cell factor C1 Homo sapiens 208-213 3015377-1 1986 Evidence suggests that the anticancer agents etoposide (VP16-213) and teniposide (VM26) produce DNA breaks and cytotoxicity by interaction with type II topoisomerase. Etoposide 45-54 host cell factor C1 Homo sapiens 56-60 3011257-1 1986 To evaluate postulated dose-response relationships of etoposide (VP-16) for patients with recurrent small cell carcinoma of the lung, a prospectively randomized study was undertaken. Etoposide 54-63 host cell factor C1 Homo sapiens 65-70 3016271-3 1986 It has been reported that the action of etoposide (VP-16) (14) as an antitumor agent is mediated through its interaction with DNA topoisomerase II which results in DNA breakage inside the cell. Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 3012008-0 1986 Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3012008-2 1986 Recently, the combination of etoposide (VP-16) and cisplatin in this setting has been reported to result in up to 50% response rates. Etoposide 29-38 host cell factor C1 Homo sapiens 40-45 3724190-0 1986 Etoposide (VP-16) plus cisplatin (DDP): a new active chemotherapeutic combination in patients with stage III-IV ovarian adenocarcinoma. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3724190-1 1986 Ten patients with Stage III-IV ovarian adenocarcinoma were treated with the drug combination etoposide (VP-16) plus cisplatin (DDP). Etoposide 93-102 host cell factor C1 Homo sapiens 104-109 3084428-0 1986 Cytogenetic effects of etoposide (VP-16) on human lymphocytes; with special reference to the relation between sister chromatid exchange and chromatid breakage. Etoposide 23-32 host cell factor C1 Homo sapiens 34-39 3963859-0 1986 [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia]. Etoposide 1-10 host cell factor C1 Homo sapiens 12-17 4061373-0 1985 Phase II study of etoposide (VP-16) in the treatment of advanced head and neck cancer. Etoposide 18-27 host cell factor C1 Homo sapiens 29-34 3002282-0 1986 [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group]. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 3830728-1 1985 Antitumor effect and toxicity of etoposide (VP 16) in combination with cis-diamminedichloroplatinum (DDP) were studied on the in vitro C108 line and its in vivo counterpart, the M1087 line, both deriving from Lewis lung carcinoma. Etoposide 33-42 host cell factor C1 Homo sapiens 44-49 3936181-1 1985 Cisplatin (Platinol)-containing regimens, especially in combination with etoposide (VP-16) (VePesid), vindesine, and/or mitomycin-C, have proven beneficial to patients with non-small-cell lung cancer. Etoposide 73-82 host cell factor C1 Homo sapiens 84-89 3936181-1 1985 Cisplatin (Platinol)-containing regimens, especially in combination with etoposide (VP-16) (VePesid), vindesine, and/or mitomycin-C, have proven beneficial to patients with non-small-cell lung cancer. Etoposide 92-99 host cell factor C1 Homo sapiens 84-89 3835288-0 1985 [A phase II trial of etoposide (VP-16) administered intravenously in the treatment of malignant lymphoma and acute leukemia]. Etoposide 21-30 host cell factor C1 Homo sapiens 32-37 4060251-0 1985 Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer. Etoposide 34-43 host cell factor C1 Homo sapiens 23-28 4061373-1 1985 Eighteen patients with advanced and heavily pretreated squamous cell carcinoma of the head and neck were treated with etoposide (VP-16). Etoposide 118-127 host cell factor C1 Homo sapiens 129-134 3931320-1 1985 In June 1981 the authors activated a trial to evaluate the therapeutic effectiveness of the combination mitomycin C (MMC) + etoposide (VP 16) in previously untreated gastric carcinoma with measurable neoplastic lesions. Etoposide 124-133 host cell factor C1 Homo sapiens 135-140 4004921-0 1985 Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): implications for mode of action. Etoposide 64-73 host cell factor C1 Homo sapiens 75-80 4015122-0 1985 [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas]. Etoposide 19-28 host cell factor C1 Homo sapiens 30-35 3859585-0 1985 Etoposide (VP-16) with prednisone and vincristine for the treatment of refractory acute lymphoblastic leukemia. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3895100-2 1985 In a phase I/II study the tolerable doses and antileukemic efficacy of the combination AMSA and etoposide (VP 16-213) was assessed in 20 patients with refractory acute myeloid leukemia. Etoposide 96-105 host cell factor C1 Homo sapiens 107-112 3884152-1 1985 Bioavailability of an oral preparation of the antineoplastic drug etoposide (VP-16) was studied in 13 patients with advanced malignancies. Etoposide 66-75 host cell factor C1 Homo sapiens 77-82 2983434-0 1985 High-dose etoposide (VP-16) in small-cell lung cancer. Etoposide 10-19 host cell factor C1 Homo sapiens 21-26 2983434-1 1985 Etoposide (VP-16) is one of the most active drugs against small-cell lung cancer. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 3883504-0 1985 Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: report from the Lung Cancer Treatment Study Group. Etoposide 30-39 host cell factor C1 Homo sapiens 41-46 3975657-0 1985 Bioavailability and pharmacokinetics of etoposide (VP-16). Etoposide 40-49 host cell factor C1 Homo sapiens 51-56 3864390-11 1985 The combination of DDP and VP-16 (etoposide) was tested most often, followed by Bleo (bleomycin) as a single agent. Etoposide 34-43 host cell factor C1 Homo sapiens 27-32 4039635-0 1985 Cis-dichlorodiammineplatinum (cis-platinum) and etoposide (VP-16) in malignant lymphoma--an effective salvage regimen. Etoposide 48-57 host cell factor C1 Homo sapiens 59-64 4039984-0 1985 Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma. Etoposide 67-76 host cell factor C1 Homo sapiens 78-83 2990749-0 1985 Drug monitoring of etoposide (VP16-213). Etoposide 19-28 host cell factor C1 Homo sapiens 30-34 2990749-7 1985 Preliminary pharmacokinetic data for etoposide (VP16-213) together with calibration data are presented, and are discussed with reference to the sensitivity and detection limit of the new experimental method. Etoposide 37-46 host cell factor C1 Homo sapiens 48-52 3007254-0 1985 [Ifosfamide and adriamycin after induction with cisplatin and etoposide (VP-16) in pulmonary microcytoma. Etoposide 62-71 host cell factor C1 Homo sapiens 73-78 2981292-3 1985 Patients not in complete remission after the four cycles of AVC received two courses of VP-16 (etoposide) and cisplatin: the complete remission rate increased to 49% and 48% respectively. Etoposide 95-104 host cell factor C1 Homo sapiens 88-93 2981293-0 1985 Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 2981293-1 1985 Seventy-eight patients with evaluable small-cell lung cancer (SCLC) were treated with etoposide (VP-16) and cisplatin after their disease failed to respond to, or relapsed after, induction combination chemotherapy, consisting primarily of cyclophosphamide, doxorubicin (Adriamycin), and vincristine (CAV). Etoposide 86-95 host cell factor C1 Homo sapiens 97-102 3839284-0 1985 Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Etoposide 24-33 host cell factor C1 Homo sapiens 17-22 6095666-1 1984 Thirty-seven patients with persistent or metastatic gestational trophoblastic disease were treated with oral etoposide (VP16-213). Etoposide 109-118 host cell factor C1 Homo sapiens 120-124 6208991-9 1984 VP-16 (etoposide) has just become commercially available and is an important drug both in leukemia and lymphoma. Etoposide 7-16 host cell factor C1 Homo sapiens 0-5 6380707-4 1984 These clones also showed cross-resistance to deoxyadenosine and thymidine, but normal sensitivity to arabinosylcytosine and adenosine, and increased sensitivity to the etoposide VP16-213. Etoposide 168-177 host cell factor C1 Homo sapiens 178-182 6366676-0 1983 [Results of drug therapy of inoperable non-small cell lung carcinoma with VP 16-213 (Etoposide) and cis-platin. Etoposide 85-94 host cell factor C1 Homo sapiens 74-79 6539169-0 1984 Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Etoposide 20-29 host cell factor C1 Homo sapiens 31-35 6204257-3 1984 In addition, etoposide (VP-16) was used in seven patients, bleomycin in six, cisplatin in five, 5-fluorouracil in two, and cis-retinoic acid in four patients. Etoposide 13-22 host cell factor C1 Homo sapiens 24-29 6539305-1 1984 A human tumour cell line resistant to etoposide ( VP16 -213) has been produced by fractionated X-irradiation exposure in vitro. Etoposide 38-47 host cell factor C1 Homo sapiens 50-54 6690078-0 1984 Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer. Etoposide 29-38 host cell factor C1 Homo sapiens 18-23 6481426-0 1984 Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. Etoposide 22-31 host cell factor C1 Homo sapiens 15-20 6318994-0 1983 Etoposide (VP-16) in the treatment of lung cancer. Etoposide 0-9 host cell factor C1 Homo sapiens 11-16 6684989-0 1983 Combined chemotherapy with ifosfamide and cisplatin and with ifosfamide and etoposide (VP-16) in non-small cell carcinoma of the bronchus. Etoposide 76-85 host cell factor C1 Homo sapiens 87-92 7127332-0 1982 Proceedings of the German Cancer Society (Clinical Oncology Section) and Bristol-Myers GmbH Symposium on Etoposide (VP-16). Etoposide 105-114 host cell factor C1 Homo sapiens 116-121 6686849-0 1983 Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer. Etoposide 55-64 host cell factor C1 Homo sapiens 66-70 6686849-1 1983 Sixty-eight patients with non-small cell lung cancer were treated in a prospectively randomized study with cyclophosphamide, doxorubicin (Adriamycin), and etoposide (VP16-213) with cisplatinum (CAE +/- P). Etoposide 155-164 host cell factor C1 Homo sapiens 166-170 6678864-1 1983 The epipodophyllotoxin derivatives, etoposide (VP-16) and teniposide (VM-26), are highly lipophilic anticancer drugs supplied with novel commercial solvent systems. Etoposide 36-45 host cell factor C1 Homo sapiens 47-52 6290053-0 1982 Small-cell bronchogenic carcinoma--primary and relapse therapy with etoposide (VP-16), methotrexate and CCNU. Etoposide 68-77 host cell factor C1 Homo sapiens 79-84 7160031-0 1982 [Etoposide: VP-16]. Etoposide 1-10 host cell factor C1 Homo sapiens 12-17 7083450-0 1982 Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors. Etoposide 0-9 host cell factor C1 Homo sapiens 11-15 7044594-0 1982 VP16-213 (etoposide). Etoposide 10-19 host cell factor C1 Homo sapiens 0-4 7083455-0 1982 Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Etoposide 42-51 host cell factor C1 Homo sapiens 53-57 7083456-2 1982 Previous studies in vitro on the influence of extracellular protein binding of Teniposide (VM26) and Etoposide (VP16-213) on subsequent cellular uptake by experimental murine tumor cells [Cancer Res 38:2549 (1978); Drug Metab Rev 8:119 (1978)] suggested that a timed-sequential combination of VM26 and VP16-213 may increase the bioavailability of VP16-213. Etoposide 101-110 host cell factor C1 Homo sapiens 112-116 7083457-0 1982 A phase I trial of continuous infusion VP16-213 (etoposide). Etoposide 49-58 host cell factor C1 Homo sapiens 39-43 7083462-0 1982 The role of VP16-213 (etoposide; NSC-141540) in gestational choriocarcinoma. Etoposide 22-31 host cell factor C1 Homo sapiens 12-16 7083462-1 1982 Since 1976 we have used VP16-213 (Etoposide; NSC-141540) in several groups of patients with gestational choriocarcinoma. Etoposide 34-43 host cell factor C1 Homo sapiens 24-28 33570788-10 2021 Furthermore, the overexpression of PLAC8 promoted cell viability and proliferation, acting as a protective mechanism of trophoblasts against the cytotoxicity of etoposide (VP-16). Etoposide 161-170 host cell factor C1 Homo sapiens 172-177 7031350-0 1981 [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author"s transl)]. Etoposide 1-10 host cell factor C1 Homo sapiens 11-16